Targeting proteins for ubiquitination and degradation in the treatment of human disease by Sakamoto, Kathleen Miho
TARGETING PROTEINS FOR
UBIQUITINATION AND DEGRADATION
IN THE TREATMENT OF HUMAN
DISEASE
Thesis by
Kathleen Miho Sakamoto
In Partial Fulfillment of the Requirements for the
degree of
Doctor of Philosophy
CALIFORNIA INSTITUTE OF TECHNOLOGY
Pasadena, California
2003
(Defended December 18, 2003)
ii
„ 2004
Kathleen M. Sakamoto
All Rights Reserved
iii
ACKNOWLEDGEMENTS
At Caltech, I would like to thank my mentor and PI, Ray Deshaies, for allowing
me to pursue my dream of obtaining a Ph.D.  Without his guidance and mentorship, this
would not have been possible.  The road to achieving my degree has been unconventional
to say the least, and Ray understood that I had other responsibilities, including my own
grants and papers in addition to my clinical duties at UCLA.  I would like to thank the
members of the Deshaies lab, especially Rati Verma, for their input and suggestions, and
inspiring me to be a better scientist.    I am grateful to the STAR program at UCLA and
Caltech, for allowing me to participate in the graduate program.   I would also like to thank
David Baltimore, Bill Dunphy, Elliot Meyerowitz, and Paul Sternberg, for taking the time
from their busy schedules to be members of my committee.
At UCLA, I would like to thank my mentors, Drs. Ed McCabe and Stephen Feig,
for their support of my graduate work.  They provided me with protected time from clinical
and administrative duties so that I could complete my experiments.  They encouraged me
throughout my thesis work and recognized the importance of completing my project.  I also
want to express my appreciation to the members of my laboratory at UCLA, who were
patient and flexible as I often communicated with them through email and phone calls
while at Caltech.
Finally, I would like to thank my husband, Ken, for his patience and
encouragement as I pursued my doctoral degree.  This degree is dedicated to my parents
who taught me the importance of hard work, dedication, discipline, and pursuit of
knowledge from an early age.
This work was supported by the Jonsson Comprehensive Cancer Center, UC Biostar
Program/Celgene-Signal Pharmaceuticals, CaPCURE, Susan G. Komen Breast Cancer
Foundation, Department of Defense, UCLA Stein Oppenheimer Endowment Fund, and
UCLA Specialized Program of Research Excellence (SPORE) in Prostate Cancer.
iv
ABSTRACT
           Protein degradation is one of the tactics employed by the cell for irreversibly
inactivating proteins. In eukaryotes, ATP-dependent protein degradation in the cytoplasm
and nucleus is carried out by the 26S proteasome.  Most proteins are targeted to the 26S
proteasome by covalent attachment of a multiubiquitin chain.  A key component of the
enzyme cascade that results in attachment of the multiubiquitin chain to the target or labile
protein is the ubiquitin ligase that controls the specificity of the ubiquitination reaction.
Defects in ubiquitin-dependent proteolysis have been shown to result in a variety of human
diseases, including cancer, neurodegenerative diseases, and metabolic disorders.
     The SCF (Skp1-Cullin-F-box-Hrt1) complex is a heteromeric ubiquitin ligase that
multiubiquitinates proteins important for signal transduction and cell cycle progression.  A
technology was developed known as Protac (Proteolysis Targeting Chimeric Molecule),
that acts as a bridge, bringing together the SCF ubiquitin ligase with a protein target,
resulting in its ubiquitination and degradation.  The Protac contains a peptide moiety at one
end that is recognized by SCF that is chemically linked to the binding partner or ligand of
the target protein.  The first demonstration of the efficacy of Protac technology was the
successful recruitment, ubiquitination, and degradation of the protein Methionine
Aminopeptidase-2 (MetAP-2) through a covalent interaction between MetAP-2 and Protac.
Subsequently, we demonstrated that Protacs could effectively ubiquitinate and degrade
cancer-promoting proteins (estrogen and androgen receptors) through non-covalent
interactions in vitro and in cells.  Finally, cell-permeable Protacs can also promote the
degradation of proteins in cells.  Biologically, this work signifies the amazing versatility
and flexibility of the ubiquitin-proteasome system.  Technologically, this work represents
v
the development of a novel “chemical genetics” approach to selectively target proteins for
degradation. Practically, this work is “Proof of Concept” that exploiting the cell’s natural
proteolytic machinery is a potential avenue for the treatment of human disease.
vi
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NOMENCLATURE
SCFb-TRCP.  Skp1-Cullin-Fbox
Protac.  Proteolysis Targeting Chimeric Molecule
E2.  Estradiol
DHT.  Dihydroxytestosterone
Methionine aminopeptidase-2. MetAP-2
ER.  Estrogen receptor
AR.  Androgen receptor
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C h a p t e r  I
INTRODUCTION
Ubiquitin (Ub)-dependent proteolysis of key regulatory proteins impacts various
cellular processes such as cell cycle progression, transcription, antigen presentation,
receptor endocytosis, fate determination, and signal transduction  (1, 2).  With so many
cellular pathways affected, it is therefore not surprising that derangements in the Ub-
proteolytic pathway contribute to the etiology of several diseases. In this review, we will
summarize our current understanding of how Ub-dependent degradation takes place in the
cell, and the various steps at which an impairment of the normal pathway contributes to the
diseased state. We will conclude by summarizing the different ways we, as well as others,
are utilizing the cellular degradation machinery to develop therapeutic strategies to treat
human diseases.
BACKGROUND
The Ubiquitin System
Ubiquitin is one of the most conserved proteins in eukaryotes.  It is a small 76-
amino acid protein that is conjugated to other proteins through an energy-dependent
enzymatic pathway (1, 3).  Conjugation is initiated by the activation of Ub by the Ub-
activating enzyme, E1, which forms a high-energy Ub-thiol ester bond in the presence of
ATP.  It then transfers the activated Ub to a Ub-conjugating enzyme, E2, forming an E2-
thiol ester bond.  Finally, ubiquitin is transferred to a target substrate protein through an
isopeptide linkage between the conserved C-terminal glycine residue of ubiquitin and the e-
amino group of the lysine residue of the substrate.  In many cases, the transfer of ubiquitin
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from an E2 to a target protein requires the involvement of a ubiquitin ligase, E3, which is
discussed in the next section.  Sequential conjugation of the internal lysine residue of
ubiquitin to a C-terminal glycine residue of a new ubiquitin molecule results in formation
of a polyubiquitin chain, which targets proteins for degradation by the 26S proteasome
(Fig. 1) (4, 5).
       
Fig. 1
Ubiquitin Ligases
The E3 ubiquitin ligases cooperate with E2 ubiquitin conjugating enzymes to assemble
multi-ubiquitin chains on substrate proteins.  Generally, ubiquitin ligases, whether
monomeric, or multimeric complexes, contain domains that recognize substrate proteins
specifically, as well as domains that interact with E2 enzymes, thereby promoting ubiquitin
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transfer from the E2 to the substrate.  Based on sequence homology and catalytic
mechanisms, all known ubiquitin ligases can be divided into two major classes: the
catalytic HECT domain E3s, and the adaptor RING finger based E3s (4, 6). Variants of the
latter class, the PHD domain containing E3s and the U box E3s are only now beginning to
be defined  (7-9).
The HECT domain proteins are found in all eukaryotes and are defined by a 350
amino acid C-terminal HECT homology domain (Homologous to E6-AP C-Terminus),
originally identified in E6-AP (10).  E6-AP is the cellular ubiquitin ligase recruited by the
human papilloma virus E6 oncoprotein to induce degradation of the p53 tumor suppressor.
Multiple HECT domain proteins have been identified, including RSP5, UFD4, and TOM1
in S. cerevisiae; Pub1 in S.pombe, and NEDD4 in humans.  The large N-terminal domains
allow the ligases to bind substrates and the C-terminal HECT domains serve to directly
transfer ubiquitin to the substrates through an E1-E2-E3 ubiquitin thiol ester cascade. Thus
this class of ligases functions catalytically (6, 11).
The identification of RING finger domains in SCF (Skp1-Cullin-F box) and other
non-HECT domain ubiquitin ligases suggested that these domains function to ubiquitinate
proteins.  The RING domain is a zinc-binding motif that is defined by an octet of cysteine
and histidine residues in a consensus sequence CX2CX (9-39)CX(1-3)HX(2-
3)C/HX2CX(4-48)CX2C (4, 6, 12). RING finger E3s play prominent roles in diverse
cellular processes, including cell cycle progression, signaling, transcription, apoptosis,
proliferation and DNA repair.
The SCF subfamily of E3s was originally discovered and studied in budding yeast
S. cerevisiae.  The SCF complex consists of at least four subunits: CUL1/CDC53,
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HRT1/RBX1/ROC1, SKP1 and an F-box protein (4, 13, 14).  The known SCF subunits are
conserved throughout evolution.  The Cullin and the RING finger protein HRT1 form a
catalytic core of E3s that binds to and activates E2 CDC34 or UBCH5 (15, 16). HRT1 is a
small 121 amino acid RING finger protein that binds directly to Cullins and CDC34, likely
tethering E2 to the CH domain, which is confirmed by the crystal structure (17).   SKP1
binds to the CDC53/HRT1 core and mediates recruitment of various F-box adapter
proteins, which contain a 45 amino acid motif called an F-box and bind to substrates
through protein-protein interaction domains, thus conferring substrate specificity to this
family of E3s.  Multiple F-box proteins have been shown to bind SKP1. There are over 400
F-box proteins currently in the database, with 20 F-box proteins in S. cerevisiae, over 100
in C. elegans, and over 50 described so far in mammals (18).
Many proteins have been demonstrated to be substrates of SCF ubiquitin ligase (4).
These proteins participate in a variety of cellular functions, including regulation of cyclin
dependent kinase activity, activation of transcription, signal transduction and DNA
replication.  In all cases of SCF Ub-ligases working in conjunction with the Cdc34 E2
enzyme, phosphorylation of the substrates is required for recognition by the F-box proteins.
For SCFCDC4, each of the known substrates, SIC1 (14, 19), CDC6 (20), and GCN4 (21, 22),
FAR1(23), must be phosphorylated before they can be recognized by the WD40 domain of
CDC4 and ubiquitinated.  Another WD40-repeat protein, b-TRCP, forms a complex with
SCF and recognizes a specific phosphoserine motif found in its substrates IkBa and b-
catenin (24-26).  This mechanism allows for differential and temporal regulation of SCF
substrate stability in the presence of fully active SCF complexes.
5
SCF might serve as a prototype for other modular Cullin-based ubiquitin ligases.
There are at least five other human cullins, which do not bind SKP1.  Human CUL2 binds
to the Von Hippel-Lindau gene product (VHL) through Elongin B and Elongin C (which
shares homology with the N-terminal region of SKP1) to form a complex (CUL2-VBC)
that displays ubiquitin ligase activity (27).  VHL down-regulates hypoxia-inducible
mRNAs presumably by controlling proteolysis of hypoxia regulated transcription factors
HIF1a and HIF2a (28, 29). Human CUL3 was recently shown to ubiquitinate Cyclin E and
control S phase in mammalian cells (30).  Human CUL4 associates with UV-damaged
DNA binding protein and appears to play a role in DNA repair (31, 32).
Another prominent RING finger containing E3 is the Anaphase Promoting Complex
(APC/Cyclosome), which is required for metaphase to anaphase transition and mitotic exit
(33).  APC is a multisubunit ubiquitin ligase that consists of at least 12 proteins, including
Cullin family member APC2 and a RING-H2 protein APC11 (34, 35).  As with SCF, APC
associates with WD repeat-containing adapter proteins CDC20/fizzy and
CDH1/HCT1/Fizzy-related that activate APC toward specific substrates (36).
A subclass of ubiquitin ligases is the Plant homeodomain (PHD) or Leukemia
associated-protein (LAP) domain containing E3s, which have eight conserved metal
binding ligands (C4HC3) with similar spacing to ring finger ligases, to which they are
closely related structurally (37).  The PHD/LAP domain is found in more than 400
eukaryotic proteins, many of which are involved in regulating gene expression (38).  PHD
domains have been reported to have a variety of functions, including protein-protein
interaction and binding to DNA.  Recently, it was shown that the MEKK1 PHD domain
has E3 ubiquitin ligase activity, suggesting at least in some cases, these proteins may
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behave as E3s (7).  Naturally occurring mutations have been identified in several diseases,
such as ING1 in head and neck squamous cell carcinomas (39), AIRE in autoimmune
polygladular syndrome, type I (40), and MLL and CBP in myeloid leukemias (41).
Furthermore, genes encoding PHD proteins have been identified in deletion regions of
several continuous gene deletion syndromes such as Williams syndrome (42).  The
occurence of mutations in PHD domains suggests that the PHD domain E3 activity could
play an important role in human disease (43).
Recently, a sequence-profile analysis demonstrated that the U box is a derived
version of the RING-finger domain that lacks the metal-chelating  residues but is likely to
function similarly to the RING-finger in mediating ubiquitin-conjugation of protein
substrates.  Interestingly, the signature cysteines of the RING finger are not conserved in
the U box.  Multiple alignment of the U box with selection of RING fingers shows that,
except for the loss of the hallmark cysteines and a histidine, the U box retains the same
pattern of amino acid residue conservation.  Thus, the U box, like the RING finger are
likely to activate ubiquitination and multi-ubiquitination by facilitating the interaction
between E2 proteins and their substrates (9).
Protein Degradation in Human Disease
Diseases arising due to impairment of ubiquitin ligases
Cervical cancer
Among the best-characterized associations between cancer and the ubiquitin ligase
pathway is that of cancer of the uterine cervix. This is the third most common cancer
diagnosed in women.  While the precise cause of cervical cancer remains uncertain, the
disease is strongly associated with infections by the oncogenic forms of HPV, types 16 and
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18.  The E6 and E7 proteins of these high risk strains are often detected in cervical cancers
(44).  In these same carcinomas, the levels of tumor suppressor p53 are very low,
suggesting a link between E6 and p53.  In fact, the p53 protein forms a ternary complex
with high risk HPV E6 oncoprotein E6-16 or –18 and the ubiquitin ligase E6-AP (10).  E6-
AP can interact with E6 in the absence of p53, but can only interact with p53 in the
presence of E6.  The E6/E6-AP complex promotes ubiquitination of p53, resulting in
degradation by the 26S proteasome.  The strong correlation between different
polymorphisms of p53 to E6-mediated destruction and the prevalence of cervical
carcinoma in women further supports the link between p53 degradation by the ubiquitin
pathway and malignant transformation.  The tumor suppressive effects of p53 are most
likely exerted through its apoptotic function or checkpoint activity such that accelerated
degradation promotes malignant transformation.
SCF complex and cancer
The invariant subunits of SCF are the E2-interacting subunits Hrt1/ROC1,
Cdc53/Cul1, and the F-box interacting protein Skp1. The subunit that varies is the F-box
containing protein that confers substrate specificity. Thus the specific form of the SCF
ligase is denoted by a superscript. Besides SCFCdc4, SCFSkp2 is another form of the ligase
whose substrate is the cyclin-dependent kinase (cdk) inhibitor, p27Kip1.  Recently, a cdk
subunit known as Cks1 was found to direct ubiquitin-mediated proteolysis of the CDK-
bound p27Kip1 by SCFSkp2 (45).  The p27 protein plays a major role in maintaining
differentiated mammalian cells in a quiescent state by negatively regulating the activities of
cyclin-dependent kinases required for initiation of DNA synthesis and inhibiting G1 to S
transition (46).  The p27 protein is unstable and expressed at low levels in many cancers
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(47).  In many cases, decreased p27 expression is associated with a worse prognosis (48,
49). Further support for the role of Skp2 in regulation of p27 levels in vivo, mouse
embryonic stem cells lacking the Skp2 gene express elevated levels of p27 (50).
Regulation of G1 to S transition in the mammalian cell cycle occurs through the
activation of cyclin dependent kinases (Cdks) 2, 4, and 6.  The cyclin that regulates Cdk2,
Cyclin E, is targeted for ubiquitin-mediated proteolysis by an SCF ubiquitin ligase that
contains the human homologue of yeast Cdc4, which is an F-box protein containing
WD40 repeats.  Recently, the F box protein Cdc4 was found to be mutated in breast
cancer cells that express high levels of cyclin E (45).  In one breast cancer cell line, a
tandem duplication consisting of a direct repeats of exons 8 and 9 separated by 11 base
pairs of intronic sequence.  This mutation was predicted to result in chain termination,
eliminating the last four WD40 repeats, rendering the truncated Cdc4 nonfunctional.
Interestingly, aberrant hCdc4 mRNA levels, loss of hCdc4 protein, and loss of
heterozygosity in these cell lines were also observed (45).
Targets for SCFb-TRCP ubiquitin ligase include the transcription factor b-catenin and
IkB, the inhibitor of the transcription factor NF-kB (25, 26, 51).  SCFb-TRCP complexes
recruit phosphorylated b-catenin and IkB for ubiquitination by the E2 enzyme Cdc34 as
well as ubch5.  b-catenin functions as a transcription factor in the Wnt/wingless signaling
pathway (52).  The Wnt/wingless family of secreted proteins act as inducers of axis
formation and organogenesis in embryonic patterning pathways of many developing
tissues.  In the absence of a Wnt/wingless signal,  b-catenin is rapidly phosphorylated by
the glycogen synthase 3-b (GSK-3b) kinase in a reaction that requires axin and the
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adenomatous polyposis coli (APC) tumor suppressor protein.  Phosphorylated b-catenin is
targeted for ubiquitination by the SCFb-TRCP complex and degraded by the proteasome (53).
In the presence of a Wnt/wingless signal, b-catenin is not phosphorylated and
ubiquitinated.  The levels of transcriptionally active b-catenin rise, which results in
activation of b-catenin-regulated gene expression.  Mutations of b-catenin phosphorylation
sites, as well as APC mutations also block ubiquitination and degradation of b-catenin and
often result in inappropriate expression of b-catenin-regulated genes and in cancer (52, 54).
Recent work has suggested that a complex of casein kinase I and axin induces b-catenin
phosphorylation at serine 45 that initiates the degradation cascade and serves as a
molecular switch for the Wnt pathway (55).
SCFb-TRCP complex and immune modulation
The SCFb-TRCP complex also participates in activation of transcription factor NF-kB by
targeting the inhibitor IkB for ubiquitination and degradation by the proteasome, as well as
being implicated in processing of the p105 precursor.  Extracellular signals mediated by
cytokines, such as TNFa activate phosphorylation of IkB by the IkB kinases (56).
Phosphorylated IkBa is targeted for ubiquitination by the SCFb-TRCP complex and degraded
by the proteasome, resulting in nuclear translocation of NF-kB and activation of expression
of NF-kB-regulated genes.  More recent work demonstrated that the signal transducer in
the NF-kB pathway, TRAF6, a ring domain protein, functions together with a ubiquitin
conjugating enzyme Ubc13/Uev1A to catalyze the synthesis of unique polyubiquitin chains
linked through lysine 63 (K63) of ubiquitin.  Inhibition of this polyubiquitin chain synthesis
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prevents the activation of IKK by TRAF6 (57).  This suggests a new role for ubiquitination
in immune regulation.
von Hippel-Lindau (VHL) disease
The VHL syndrome is an autosomal dominant familial cancer syndrome that
predisposes affected individuals to tumors, including cerebellar hemangioblastomas,
hemangiomas, renal cell carcinomas, retinal angiomas, and pheochromocytomas (58).  The
VHL tumor suppressor gene is located on chromosome 3p25.5 and is mutated in the
majority of sporadic clear cell renal carcinomas in addition to tumors associated with the
VHL syndrome.  The VHL protein resides in the cytoplasm but can translocate to the
nucleus that is Ran and energy-dependent.  VHL forms stable, multimeric complexes that
contains Elongin B, Elongin C, Cul2, and Rbx1 (59).  The knowledge that Elongin C
resembles Skp1 adaptor protein of SCF and VHL associates with the cullin family member
Cul2, suggested that the VHL/Elongin/Cul2 complex might function similarly to SCF in
yeast.  The crystal structure of VHL bound to Elongin B and C showed that the region of
VHL that binds to Elongin C loosely resembles an F-box and that Elongin C resembles
Skp1 (29). Mutations found in VHL disease clustered in two regions that are critical for
complex formation and potentially substrate recognition.  Furthermore, anti-VHL
immunoprecipitates contained ubiquitin ligase activity, indicating that VHL was associated
with ubiquitination.  It is now known that VHL ubiquitinates HIF transcription factor,
which regulates hypoxia inducible genes and is degraded in the presence of oxygen (59).
Furthermore, VHL binds to a short HIF-derived peptide on a conserved proline residue
only when the peptide is hydroxylated. Since proline hydroxylation requires molecular
11
oxygen and Fe2+ , this modification most likely plays a critical role in oxygen sensing in
mammalian cells (59).
Clear cell renal carcinoma cells lack a functional VHL protein and exhibit a diverse
array of phenotypes including cell cycle defects (60), overexpression of TGFb (61), defects
in endoplasmic reticulum associated degradation of misfolded proteins (62), and defects in
assembly of extracellular matrix (63).   One interesting feature of VHL tumors is their high
vascularity, which is thought to result from deregulation by VHL of hypoxia-inducible
genes including the angiogenesis-promoting factor vascular endothelial growth factor
(VEGF)(64, 65).  The expression of VEGF and other hypoxia-regulated genes are
repressed under normoxic growth conditions in cells, but are strongly induced under
hypoxic conditions and constitutively expressed in cells lacking functional VHL.
Cbl ubiquitin ligase and cancer
Cbl is an adapter protein that contains both SH2 and RING-HC finger domains.
Cbl functions as a monomeric ubiquitin ligase that recognizes phosphorylated tyrosine on
receptor tyrosine kinases (RPTKs) through its SH2 domain and negatively regulates
signaling by promoting active receptor ubiquitination and degradation (66-70).  Oncogenic
versions of Cbl containing deletions or point mutations in the C-terminal tyrosine kinase
binding domain resulted in transformation.  Another oncogenic form of c-Cbl, termed 70Z-
Cbl, exhibits a 17-amino acid deletion that removes C381, the first cysteine residue of the
RING finger, and most of the linker domain between TKB and the RING finger. These
mutants lack E3 activity, suggesting that they act as dominant-negative proteins competing
with wild-type c-Cbl for tyrosine-phosphorylated tyrosine kinases abrogating the negative-
regulatory effect of c-Cbl in cell signaling (68).
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Angelman’s Syndrome
Angelman’s syndrome is a rare neurological disorder characterized by mental
retardation, seizures, absence of speech, excessive laughter, and abnormal gait.  The
affected gene is the E3 ubiquitin ligase E6-AP.  It is thought that the syndrome results from
aberrant accumulation of substrates of E6-AP (71).  Although the targets are unknown,
studies have suggested a role for E6-AP in brain development.  Studies also show that
mutation of the E6-AP ubiquitin ligase reduces nuclear inclusions and accelerate
polyglutamine-induced neurodegeneration (72).
Parkinson’s disease
One of the most common forms of familial Parkinson’s disease is the autosomal
recessive juvenile Parkinsonism (AR-JP).  AR-JP is characterized by selective
dopaminergic neural cell death and the absence of the Lewy body, a cytoplasmic inclusion
body consisting of aggregates of abnormally accumulated proteins (73).
AR-JP was first described by Yamamura and colleagues (74).  The gene was
mapped to chromosome 6q25.2-q27 and contains 12 exons with a molecular mass of 52
kDa.  This gene is highly conserved throughout evolution, including Drosophila, c.
elegans, and mammals.  The N-terminus of Parkin demonstrates a ubiquitin-like domain,
while the C-terminal half region of Parkin has two RING-finger motifs.  Parkin is thought
to act as a ubiquitin ligase through association with the ubiquitin-conjugating enzyme
UbcH7.  Mutations in Parkin in AR-JP patients demonstrate decreased ubiquitin ligase
activity (75).  Recent findings suggest that accumulation of proteins that are substrates of
Parkin causes selective neuronal cell death without formation of Lewy bodies.
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Further link between Parkinson’s Disease and the ubiquitin system has been
suggested in the studies of two gene products, UCH-LI (ubiquitin carboxyl-terminal
hydrolase) and a-synuclein, whose mutations cause autosomal dominant familial
Parkinson’s Disease (76, 77). UCH-L1 is thought to regenerate ubiquitin by both cleaving
polyubiquitin chains and releasing ubiquitin from small adducts such as glutathione and
cellular amines (78).  a-Synuclein, one of the major components of Lewy bodies (79) is
degraded by the 26S Proteasome (80), suggesting that it is modified by ubiquitin, and
mutations in Parkin may extend the half-life of the protein.
Other neurological disorders including Huntington’s disease and spinocerebellar
ataxias have been thought to also result from mutant proteins that aggregate in
intranuclear accumulation bodies that fail to be degraded due to expanded
CAG/polyglutamine repeats (81, 82).  In prion diseases, pathology results from
accumulation of a conformationally altered prion protein, which forms aggregates (83).
Thus, it may be postulated that prionogenic and amyloidogenic proteins escape correct
protease and chaperone responses of the cellular quality control program.
Diseases arising due to impairment of substrates of ubiquitin ligases
Alzheimer’s disease and the ubiquitin system
In many neurodegenerative disorders, such as Alzheimer’s disease, inclusions
containing  ubiquitinated proteins have been identified in the brain, suggesting a role for
ubiquitin-dependent proteolysis of neuronal proteins.  Prevention of ubiquitination
inhibited the neurotoxic effects of b-amyloid.  In the central nervous system, proteasome-
mediated protein degradation plays a major role in the breakdown of proteins damaged by
oxidative stress or other insults, including glucose and oxygen deprivation.  Inclusions
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containing ubiquitinated proteins are commonly found in many neurogenerative disorders
(84).  Protein aggregation can also directly impair the function of the ubiquitin-proteasome
system (85).  Since b-amyloid itself could cause protein ubiquitination, and b-amyloid
toxicity can be blocked by inhibiting protein ubiquitination or proteasome activity, new
prophylactic and therapeutic avenues for treatment of neurodegenerative disease are being
developed.  Pharmacological inhibition of ubiquitination or proteasome-mediated
degradation of ubiquitinated proteins may prevent, alleviate, or inhibit the progression of
chronic neurogenerative diseases such as Alzheimer’s disease.
Cystic fibrosis and ubiquitination
Cystic fibrosis (CF) is the most common genetic disorder and is characterized by severe
bronchopulmonary infections and pancreatic insufficiency.  The gene associated with CF
encodes a transmembrane protein (CFTR) which is a chloride ion channel normally
localized to the plasma membrane of epithelial cells.  Because it is a large protein, most of
the wild type protein is degraded from the ER by the ubiquitin system and only a small
fraction reach the cell surface.  In CF, mutations in the protein interfere with the folding of
the protein, the most common of which is DF508.  Although it is functional, the DF508
protein is completely retained in the ER, from which it is polyubiquitinated and degraded
by the proteasome (86, 87).  The efficient degradation of the mutant protein leads to a lack
of expression of DF508 CFTR at the cell surface, resulting in CF (88). In this disease, a
number of therapeutic strategies are possible, including transient transfection of airway
epithelial cells with intact CFTR; modification of the post-transcriptional quality control
mechanisms: activation of residual membrane-associated CFTR; activation of second
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messenger pathways; activation of alternative CF channels in the luminal membrane; and
inhibition of EnaC by amiloride.(88)
Wilson’s disease
Wilson’s disease is an autosomal recessive inherited disorder of copper metabolism that
leads to neuronal degeneration and hepatic cirrhosis.  The Wilson protein is a copper-
transporting P-type ATPase that when mutated, becomes trapped in the ER and is
presumed to be the molecular basis of disease (89).  Like the CFTR DF508 mutant protein,
the Wilson protein is rapidly degraded.
Liddle syndrome
In contrast to CFTR and Wilson’s protein, stabilization of a normally degraded
protein is the basis of Liddle syndrome.  This disease is an autosomal dominant form of
hypertension characterized by early onset hypertension and hypokalemia, and suppression
of plasma renin activity and aldosterone. The Liddle syndrome results from a deletion of
the proline rich region in the C-terminal b and g subchannel (ENaC), which leads to
constitutive activation of the protein.  ENaC normally has a short half-life because the a
and g chains are rapidly ubiquitinated. NEDD4 is a HECT domain protein that binds to the
proline rich motif of ENaC through a highly conserved WW domain.  Mutations in the b or
g subunits result in stabilization (90), leading to reabsorption of sodium and water and
development of hypertension.
Diabetes mellitus
The hereditary disorder diabetes mellitus has been shown to be caused by missense
mutations in the insulin receptor  (IR).  Various mutations in the IR gene have been
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reported in individuals with severe insulin resistance (91). Several of these mutations result
in decreased numbers of IRs at the cell surface, either as a consequence of impaired
processing of the mutant proreceptors and accumulation in the ER or increased degradation
of the mutant proreceptors.  Recent studies have demonstrated that the degradation of
mutant IR is preceded by a cleavage of the misfolded proreceptor, resulting in the
accumulation of two proteins, 120kDa  and 80kDa, which associate with the IR (91).  The
precise role of these interacting proteins has not been determined.
a1-antitrypsin Z
a1-antitrypsin (a1-AT) is the most common cause of infantile liver disease and
also causes adult-type emphysema. Most a1-AT-deficient individuals are protected from
liver damage by rapid degradation of the mutant a1-AT in the ER, however, some of these
patients who develop severe liver disease, there is decreased degradation of a1-AT
resulting in ER accumulation and hepatotoxicity (93). The protein appears to first
translocate in a retrograde manner into the cytosol, since components of the ubiquitin
proteasome pathway have not been shown to exist in the ER.  As in the cases of a1-
antitrypsin, CFTR, and Wilson’s protein, the ubiquitin ligases that attach the ubiquitin onto
these proteins have not been identified.
Cytolytic T cell response
The ubiquitin-proteasome system plays an important role in cellular immunity.  Peptides
from foreign antigens are presented as MHC class I molecules to elicit a cytolytic T cell
response (94).  In cells infected with viruses, viral antigens are targeted for degradation by
the ubiquitin-proteasome pathway. The display of viral peptides on MCH class I molecules
17
is a critical component of host defense.  Therefore, the ability to avoid the CTL response to
viral infections is an effective way for a virus to escape immune surveillance in the host
(95). An example is the Epstein-Barr virus (EBV) in which the Epstein-Barr nuclear
antigen (EBNA) is expressed in latently infected B lymphocytes where it persists in healthy
individuals.  It is the only viral protein regularly detected in EBV-associated malignancies
such as nasopharyngeal carcinomas and lymphomas, suggesting that escape from immune
surveillance might promote transformation (95).  The human cytomegalovirus (CMV)
avoids immune surveillance by down-regulating MCH class I.  Finally HIV utilizes an ER-
associated proteasomal degradation pathway to induce the down-regulation of its CD4
receptor in infected cells (96).  In the case of HIV, unlike EBV and CMV, the E3 that
ubiquitinates CD4 is known. Proteasomal degradation of CD4 occurs through a ternary
complex between CD4, the viral Vpu protein, and the WD protein b-TRCP, which recruits
the Skp1 adaptor protein of the SCF complex (98).  Vpu is an 81-amino acid membrane
phosphoprotein that interacts with CD4.  In HIV infected cells, expression of the viral
envelope glycoprotein precursor gp160 results in the formation of stable CD4-gp160
complexes that are trapped in the ER.  The VPU expressed in the ER then associates with
the CD4 cytoplasmic tail and recruits b-TRCP to the ER membrane.  b-TRCP, in turn,
recruits Skp1, resulting in CD4 ubiquitination by the E3 ligase, SCF.
Potential Therapeutic Applications
Given the fact that all mammalian cells have ubiquitin ligases and proteasomes,
selectively targeting proteins for ubiquitination and degradation is a potential avenue for
drug development.  Moreover, since there is recent information about the crystal structure
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of ubiquitin ligases and their substrates, one could imagine using low molecular weight
compounds to stabilize or degrade proteins to treat a variety of diseases.  Several
approaches have been considered, including gene therapy to selectively target proteins for
ubiquitin-dependent proteolysis.  Another approach has been to use chimeric molecules to
recruit disease-promoting proteins to E3s for ubiquitination and subsequent degradation.
Tyrosine kinase inhibitors also promote protein degradation through chaperones.  We will
discuss these approaches and their potential therapeutic applications.
Selective degradation of non-SCF targets by chimeric F box proteins
Recently it was shown that one could successfully engineer a substrate receptor of
an F-box protein to direct the degradation of otherwise stable cellular proteins in yeast and
in mammalian cells.  The yeast F box-containing Cdc4 protein normally targets the
phosphorylated cyclin-dependent kinase inhibitor Sic1 for degradation.  In order to target
the tumor suppressor Retinoblastoma (Rb) to the SCF machinery in yeast, derivatives of
Cdc4 were fused to the E7 protein encoded by the human papillomavirus type 16.  Using
the N-terminal 35 residues of E7 (E7N), which contains a conserved LXCXE Rb binding
motif, hybrid F box proteins were produced containing the F box/WD-40 repeat domains of
Cdc4 sufficient to bind Skp1 and the HPV-16 E7N fused in frame (99).  In yeast, Rb was
shown to be degraded in cells expressing the fusion protein. Similar hybrid proteins were
engineered using the mammalian F box containing b-TRCP fused to HPV-16 E7N. This
fusion protein targeted Rb for degradation and inhibited RB-induced growth arrest in
human osteosarcoma SAOS-2 cells.  These results suggest that the mammalian and yeast
SCF machinery could be harnessed to degrade targets that are not normally substrates of
SCF. Such an approach is a potentially useful tool to evaluate whether a protein is a target
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for drug intervention or to knock out cellular proteins to study their functions. As a
therapeutic modality, there are limitations as with other gene therapy approaches, such as
efficiency of transduction, duration of expression, and targeting to the right cells.
Ubiquitination and tyrosine kinase inhibitors
Recently, tyrosine kinase inhibitors (TKIs) have been found to not only inhibit
tyrosine phosphorylation, but also enhance ubiquitination and degradation of the receptor
tyrosine kinase, ErbB-2.  ErbB-2/HER-2 is associated with aggressive tumors, including
breast cancer. Therapy to target the oncoprotein is currently being used to treat cancer
patients.   A potent, irreversible TKI, CI-1033 was found to alkylate a cysteine residue
specific to ErbB receptors. The pathway stimulated by TKIs appears to be chaperone
mediated, and is common to the heat shock protein 90 (Hsp90) antagonist geldanamycin
through a stress-induced mechanism (100).  More recently, geldanamycin dimers and
hybrid compounds containing geldanamycin linked to estradiol or testosterone have been
shown to induce degradation of the estrogen receptor or androgen receptor, respectively, in
cancer cells (101, 102). These results suggest that selectively targeting chaperoned
oncogene products for destruction is an alternative strategy to treat human diseases such as
cancer.
Chimeric molecules to target proteins for ubiquitination and degradation
To circumvent the problem of transducing cells at high efficiency, we sought to
deliberately target a protein to the SCF complex by developing a chimeric compound,
known as a Proteolysis Targeting Chimeric Molecule (Protac).
As proof of concept, we first tested whether the Protac could recruit methionine
aminopeptidase-2 (MetAP-2) to the SCFb-TRCP for ubiquitination and degradation in vitro
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(CHAPTER II).    A Protac was synthesized that contained at one end, the minimal 10
amino acid phosphopeptide sequence of IkB that is recognized by the F-box protein b-
TRCP (26) and at the other end, the MetAP-2 binding compound, ovalicin.  MetAP-2 binds
to ovalicin covalently.  We demonstrated that the Protac could recruit the MetAP-2 to the
SCFb-TRCP complex resulting in ubiquitination.  Addition of Protac also resulted in
degradation of MetAP-2 in xenopus extracts (103).
To determine whether Protac could be generalized to other ubiquitin ligases, we
performed ubiquitination assays with Cbl (CHAPTER III).  Cbl is a monomeric ubiquitin
ligase that attaches ubiquitin to signaling molecules and receptor tyrosine kinases resulting
in proteolysis.  We generated a Protac that consisted of ovalicin and the zap70
phosphopeptide, which binds Cbl (101).  We demonstrated that Protac promotes
ubiquitination of MetAP-2 by Cbl in vitro.  These results suggest that Protac can be
generalized to other ubiquitin ligases.
Finally, to test whether Protacs could recruit a protein to the SCF for ubiquitination
and degradation of a different target that interacts through non-covalent interactions, we
targeted the estrogen receptor (ER) (CHAPTER IV).  We demonstrated that not only can
the ER be targeted to the SCF for ubiquitination, but the ubiquitinated ER is degraded by
the 26S proteasome in vitro.
Concluding remarks and future directions
The purpose of this thesis project is to establish a completely novel approach to
treating diseases by utilizing the normal function of ubiquitin ligases in cells and targeting
disease-promoting proteins for degradation.  If cell permeable Protacs prove to increase
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turnover and degrade proteins in cells, this would lead to potential therapeutic applications
in patients with cancer and other diseases.  Future work will focus on testing Protacs in
animal models of diseases, including prostate and breast cancer.  Ultimately, our goal is to
translate this strategy into clinical trials in patients with a variety of tumors and human
diseases.
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Chapter II
Protacs:  Chimeric Molecules That Target Proteins to the SCF Complex for
Ubiquitination and Degradation
The data presented in this chapter were generated in collaboration with Kyung B. Kim,
Akiko Kumagai, Frank Mercurio, and Craig M. Crews (Published in PNAS 98: 8554-8559,
2001; Appendix).
Introduction
Degradation of cellular proteins is required for normal maintenance of cellular function,
including proliferation, differentiation, and cell death.  One of the major pathways to
regulate proteins post-translationally is ubiquitin-dependent proteolysis.  Ubiquitination
occurs through the activity of ubiquitin-activating enzymes (E1), ubiquitin-conjugating
enzymes (E2), and ubiquitin-protein ligases (E3), which act sequentially to catalyze the
attachment of ubiquitin to lysine residues of substrate proteins (1).  The E3s confer
specificity to ubiquitination reactions by binding directly to substrate.  Although the exact
number of E3s can not be determined with certainty from sequence data, there are probably
>100 distinct F-box containing E3s encoded within the human genome (2).  One particular
class of E3s, the heterotetrameric SCF complexes, consists of Skp1, a Cullin family
member, the RING-H2 protein Hrt1 (also known as Roc1 or Rbx1), and an F box-protein
(3). These components are conserved from yeast to mammals.  The mammalian F-box
protein, b-TRCP/E3RS, has been shown to bind IkBa, a negative regulator of NFkB (26).
The SCFb-TRCP complex promotes the ubiquitination and subsequent degradation of IkBa ,
which results in activation of NFkB during the inflammatory response (3).
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The recruitment of IkBa to SCFb-TRCP is mediated by a ten-amino-acid peptide
within IkBa, DRHDSGLDSM (4, 5).  In response to diverse inflammatory signals,
IkBa kinase (IKK) phosphorylates this motif on both serines, which triggers binding of
IkBa to b-TRCP.  Because it is a well-defined ligand for a specific ubiquitin ligase, we
sought to take advantage of this phosphopeptide to target an unrelated protein to SCFb-TRCP
for ubiquitination and degradation.  Previous reports have indicated that dimerization and
oligomerization of proteins using synthetic ligands can be used to regulate signaling
pathways that are ligand-dependent  (6).
        As proof of concept, we tested the ability of the IkBa phosphopeptide to target
methionine aminopeptidase-2 (MetAP-2) to SCFb-TRCP.  MetAP-2  catalyzes the cleavage of
N-terminal methionine from nascent polypeptides (7).  MetAP-2 appears to be the primary
target of the potent angiogenesis inhibitors fumagillin and ovalicin (8,  9).   Both of these
compounds inhibit MetAP-2 by covalently binding histidine-231 in the active site.  The
consequent reduction in MetAP-2 activity is thought to block endothelial cell proliferation
by causing p53-dependent arrest in G1 phase of the cell cycle (10).  Importantly, MetAP-2
is not known to be ubiquitinated or a substrate for any SCF complex.
To determine whether MetAP-2 could artificially be targeted to SCFb-TRCP, we
synthesized a chimeric molecule (Protac-1; for Proteolysis-Targeting Chimeric molecule
#1) that contained both the IkBa phosphopeptide and ovalicin.  We hypothesized that the
phosphopeptide moiety would bind b-TRCP and the ovalicin moiety would bind MetAP-2,
thereby recruiting MetAP-2 to SCFb-TRCP for ubiquitination (Fig. 1).  In this paper, we
report that Protac-1 indeed binds MetAP-2 to SCFb-TRCP, and thereby promotes MetAP-2
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ubiquitination and degradation.  Demonstration that Protac-1 mediates the ubiquitination
and degradation of a foreign substrate by SCF provides a basis to begin testing Protacs in
vivo in addition to other targets known to promote disease.
Results
MetAP-2 specifically binds Protac-1 in vitro
The IkBa-ovalicin chimera, Protac-1, was synthesized as described in Materials
and Methods.  To demonstrate that purified MetAP-2 bound Protac-1, we incubated
MetAP-2 (18mM) with increasing concentrations of Protac-1 (Fig. 2A).  A Western blot
analysis was performed with anti-MetAP-2 anti-serum.  At 10 mM and 10 mM Protac-1,
we observed two bands; the lower band represents unbound MetAP-2, and the upper band
represents MetAP-2 bound to Protac-1.  Addition of Protac-1 at higher concentrations did
not increase the yield of MetAP-2–Protac-1 complexes, suggesting that only a fraction of
the MetAP-2 molecules were active and able to bind Protac-1.  Combining MetAP-2 with
either free IkBa phosphopeptide or free ovalicin did not yield the doublet observed with
Protac-1.  We also tested the specificity of MetAP-2 interaction with Protac-1 in vitro.
Free ovalicin, but not free IkBa phosphopeptide, inhibited the formation of the MetAP-
2–Protac-1 complex (Fig. 2B). Therefore, our results demonstrate that MetAP-2 was
specifically conjugated to the ovalicin moiety of Protac-1 in a concentration-dependent
manner.
Protac-1 recruits MetAP-2 to SCF
Prior to testing the activity of Protac-1, we first adapted a previously described
approach to isolate and assay SCFb-TRCP complexes in vitro (11).  Lysates from 293T cells
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transfected with plasmids that encoded b-TRCP and Cul-1 proteins tagged with the FLAG
epitope at the N-terminus were immunoprecipitated with anti-FLAG antibody conjugated
resin.  Immunoblot analysis confirmed that all components of SCFb-TRCP were present in the
anti-FLAG immunoprecipitate, including Skp1, Hrt1, and the transfected FLAGCul-1 and
FLAGb-TRCP (data not shown).  Furthermore, control experiments confirmed that these
immunoprecipitates promoted ubiquitination of IKK-phosphorylated GST- IkBa in a
manner that was inhibited by the IkBa phosphopeptide and Protac-1 (data not shown; (7)).
To determine whether Protac-1 could recruit MetAP-2 to SCFb-TRCP, we first incubated MetAP-2
(18 mM) with Protac-1 (100 mM) for 45 minutes at room temperature.  Following isolation
of SCFb-TRCP complexes, the anti-FLAG beads were supplemented with the MetAP-
2–Protac-1 mixture and rotated at room temperature for one hour.  The beads and
supernatant were then evaluated by Western blot analysis for the presence of MetAP-2.
Anti-FLAG beads coated with SCFb-TRCP, but not control beads preincubated with
untransfected 293T cell lysates, specifically retained a fraction of the MetAP-2–Protac-1
complex and not the unliganded MetAP-2 (Fig.3).  These results demonstrate that Protac-1
specifically recruited MetAP-2 to SCFb-TRCP.
Protac-1 mediates the ubiquitination of MetAP-2
Since Protac-1 was able to tether MetAP-2 to SCFb-TRCP, we next asked whether
MetAP-2 could be ubiquitinated.  To test this possibility, we supplemented anti-FLAG
beads coated with SCFb-TRCP with ATP, MetAP-2–Protac-1, plus purified E1, E2 (human
Cdc34), and ubiquitin.  Following incubation, Western blot analysis was performed with
anti-MetAP-2 antiserum.  This experiment was repeated with two different preparations of
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purified MetAP-2; one which contained primarily a 47 kDa autocatalyzed cleavage product
(Fig. 4A) and the other which contained full length 67 kDa protein (Fig. 4B).  In both
cases, MetAP-2–Protac-1 was extensively modified in the presence of SCFb-TRCP-coated
beads, but not control beads (mock).  Substitution of the methyl ubiquitin, which acts as a
chain-terminator of polyubiquitination, collapsed the high molecular weight forms of
modified MetAP-2 to a series of 2-3 bands migrating directly above unmodified MetAP-
2–Protac-1 complex (Fig. 4C, compare lanes 2 and 3 with lane 4), confirming that MetAP-
2 was ubiquitinated by SCFb-TRCP.
We next tested whether MetAP-2 ubiquitination was dependent on Protac-1.  As
shown in Fig. 4C, MetAP-2 was not ubiquitinated in the absence of either SCFb-TRCP (lane
1) or Protac-1 (lanes 5 or 6; for some experiments, methyl ubiquitin was used in place of
ubiquitin to simplify detection of ubiquitin conjugates).  Moreover, unlinked ovalicin
(50mM) plus IkBa peptide (50mM) were not able to substitute for the
ovalicin–IkBa peptide conjugate (lane 7).  Protac-1-dependent ubiquitination of MetAP-2
was specific, in that it was readily competed by free IkBa phosphopeptide (Fig. 4D, lane 3
versus lane 2).  In contrast, free ovalicin did not compete (Fig. 4D, lane 4), presumably
because it was unable to displace Protac-1 that was previously covalently linked to MetAP-
2.  Taken together, these observations indicate that Protac-1 specifically elicited
ubiquitination of MetAP-2 by SCFb-TRCP, and that successful targeting required that the two
components of Protac-1 be bound together as a chimeric molecule.
35
MetAP-2–Protac-1 is degraded in Xenopus egg extracts
The experiments described above demonstrated that MetAP-2 was ubiquitinated in
a Protac-1-dependent manner by highly purified SCFb-TRCP.  However, key issues are
whether Protac-1 can specifically activate MetAP-2 degradation, and whether targeted
degradation can be achieved by endogenous ubiquitin/proteasome pathway components at
typical intracellular concentrations.  To address these questions, we preincubated MetAP-2
with Protac-1 to allow the complexes to form, and then added the mixture to Xenopus egg
extract supplemented with constitutively active IKK (IKK-EE) (12), okadaic acid, and
ovalicin.  The addition of IKK-EE and okadaic acid was intended to sustain
phosphorylation of the IkBa peptide moiety of Protac-1, whereas ovalicin was added to
prevent the further linkage of Protac-1 to MetAP-2.  Remarkably, MetAP-2–Protac-1
complex (top band) but not MetAP-2 alone (bottom band) was mostly degraded by 30
minutes (Fig. 5).  Degradation of MetAP-2–Protac-1 was attenuated in extracts
supplemented with the proteasome inhibitors LLnL or epoxomicin (13), but not by other
protease inhibitors (chymotrypsin, pepstatin, and leupeptin) added to the reaction.
Moreover, addition of both IKK-EE and okadaic acid was required for optimal degradation
of MetAP-2–Protac-1. We have similarly seen specific turnover of the MetAP-2–Protac-1
complex, but not free MetAP-2, in 3 independent experiments.  Since the IkBa
phosphopeptide does not have lysines and the ovalicin does not have free amino groups, it
is unlikely that Protac itself serves as a target for ubiquitin-dependent proteolysis.  Taken
together, these results suggest that Protac-1 targeted MetAP-2 for degradation via the
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proteasome.  MetAP-2 turnover appeared to be very specific, in that maximal degradation
required agents predicted to sustain phosphorylation of the IkBa peptide.
Discussion
Since degradation of ubiquitinated proteins occurs rapidly in cells, we reasoned that
ubiquitin-dependent proteolysis might provide effective means to modulate the phenotype
of normal and diseased cells.  Thus, we sought to develop a method to target proteins, at
will, to the ubiquitin/proteasome pathway.  The linchpin of the strategy described here is
the development of chimeric molecules, referred to as Protacs, that link a desired target
protein to a ubiquitin ligase.  The method of ligand-regulated activation and termination of
signaling pathways with synthetic ligands has been previously reported (6).  As a target
protein for a “proof of principle” experiment, we chose MetAP-2, which covalently binds
the angiogenesis inhibitor, ovalicin.  For the ubiquitin ligase we chose the SCFb-TRCP
complex, for reasons described in more detail below.  Although MetAP-2 has 36 lysines, it
has not been reported to be an unstable protein in vivo, and it was not clear whether it
would serve as a substrate for SCFb-TRCP, no less be degraded by the ubiquitin/proteasome
pathway (14).  Our results suggest that Protac-1 can in fact recruit MetAP-2 to SCFb-TRCP
for ubiquitination.  In addition, we report that Protac-1 specifies degradation of MetAP-2
by the endogenous ubiquitin/proteasome pathway in Xenopus egg extracts.
We selected SCFb-TRCP as a candidate ubiquitin ligase for the development of Protac
technology for two reasons.  First, the apparent constitutive activity of SCF complexes
enables a general strategy to manipulate normal or diseased cells.  Second, the mechanism
underlying substrate selection is well-understood for SCFb-TRCP.  Pioneering work by Ben-
Neriah and colleagues demonstrated that a 10 amino acid internal phosphopeptide mediates
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ubiquitination and degradation of IkBa (4, 5).  Subsequently, it was established that b-
TRCP is the receptor that links this phosphopeptide to the ubiquitin/proteasome pathway
(26, 115). Furthermore, while our work was underway, Zhou, Howley, and colleagues
demonstrated that engineered SCF complexes can be used to target heterologous proteins
for destruction  (16).  Zhou et al. fused the human papillomavirus E7 protein to the F-box
proteins Cdc4 and b-TRCP to create chimeras, which assemble to form hybrid SCFCdc4-E7
and SCFb-TRCP-E7 complexes.  E7 binds tightly to Retinoblastoma protein (Rb), and the F
box protein-E7 chimeras stimulate turnover of Rb via the SCF pathway in both yeast and
mammalian cells.  A limitation of the F-box fusion approach is that it depends upon gene
transfer of the chimeric F-box protein, and thus its use is limited to transgenic organisms,
and its potential use as a therapeutic strategy awaits the development of safe and reliable
gene therapy protocols.
We propose that Protacs may be useful research tools for manipulating the
phenotype of cells through the targeted elimination of specific proteins, or useful
therapeutic agents for targeting the elimination of disease-promoting proteins.  An obstacle
to realizing these goals, however, is that the phosphopeptide-containing Protac-1 described
here is unlikely to penetrate cells.  For future applications, Protacs will need to be modified
to enhance delivery to cells.  For example, attachment of the tat peptide  (17) may promote
transduction of Protac-1 into cells, or a b-TRCP-binding peptide that is derived from the
HIV Vpu protein  (18, 19), and is phosphorylated by constitutively active Casein Kinase II,
may allow delivery of an unphosphorylated Protac to cells.  The ultimate goal is to identify
38
small molecules that can substitute for the E3-targeting activity of the
IkBa phosphopeptide.
We envision the potential to develop an entire suite of Protac compounds (Fig. II-
6).  Several approaches have been developed for identifying small molecules that bind to
any target protein of interest (20-22). Candidates emerging from such screens would serve
as platforms for the production of new Protacs, regardless of the topology of their
interaction with the target protein.  Moreover, many ubiquitin ligases have been discovered
over the past few years, and with the completion of the human genome sequence, more
ubiquitin ligases will undoubtedly follow.  Further understanding of the substrate
specificity of these ubiquitin ligases will provide insights into ways that they can be
exploited for the development of novel Protacs.
Experimental Procedure
Synthesis of IkBa-ovalicin Protac
Ovalicin (1.4 mmol) was dissolved in 10 mL of methanol at 0 oC and NaBH4 (3.0 mmol)
was added slowly. After 30 min stirring, methanol was removed under reduced pressure
and the resulting crude product was purified by flash column chromatography to yield
ovalicinol (1.15 mmol, 82%). To the ovalicinol, Fmoc-Gly was coupled to give Fmoc-Gly-
ovalicinol.  Specifically, dimethylformamide (DMF) (28 µL) was added to
dichloromethane solution (30 mL) containing Fmoc-Gly-OH (3.56 mmol) and oxalyl
chloride (7.12 mmol) at 0oC.  After 3 hour stirring at room temperature, dichloromethane
was removed under nitrogen atmosphere. The resulting solid residue was redissolved in
dichloromethane (10 mL) and was combined with ovalicinol (0.6 mmol) and
dimethylamino pyridine (DMAP) (4.7 mmol) in dichloromethane (30 mL) at 0 oC.  The
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reaction mixture was stirred for 2 hours at room temperature.  After dichloromethane was
removed under reduced pressure, the resulting residue was flash chromatographed to
provide Fmoc-Gly-ovalicinol (0.39 mmol, 65 %). Next, Fmoc-Gly-ovalicinol (0.09 mmol)
was treated with 20 % piperidine in DMF (2 mL) at room temperature for 10 minutes and
DMF was removed under high vacuum. The resulting solid was redissolved in 2 mL of
dimethylsulfoxide (DMSO) and disuccinimidyl suberate (DSS) (0.9 mmol) was added at
room temperature. After overnight stirring, DMSO was removed under high vacuum and
the resulting crude product was flash chromatographed to give monosuccinimidyl suberate-
Gly-ovalicinol (0.06 mmol, 68 %). Monosuccinimidyl suberate-Gly-ovalicinol (12 µmol)
in DMSO (0.6 mL) was added to DMSO solution (1 mL) containing IkBa peptide (3.67
µmol) and DMAP (11 µmol). After 20 min stirring at room temperature, the coupling
reaction was completed, which was confirmed by Kaiser test. DMSO was removed under
high vacuum and the resulting crude product was repeatedly washed with dichloromethane
and methanol to remove excess monosuccinimidyl suberate-Gly-ovalicinol to give the final
product (IkBa peptide-suberate-Gly-ovalicinol) (5.8 mg, 2.59 µmol, 70 %). The final
product was characterized by electrospray (ES) mass spectrometry.  ES-MS (M+H)+ for
ovalicinol-Gly-suberate-IkBa peptide:DMAP, 2,231.56. All other intermediates were
characterized by 500 MHz 1H NMR spectroscopy.
MetAP-2–Protac-1 coupling assay
MetAP-2 (9 mM) was incubated with increasing concentrations of Protac-1
(dissolved in water) at room temperature for 45 minutes.   Reactions were supplemented
with SDS loading dye, fractionated on a 10% SDS-polyacrylamide gel, transferred onto a
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nitrocellulose membrane and immunoblotted with rabbit polyclonal anti-MetAP-2
antiserum (Zymed, Inc.).  ECL was performed using Amersham detection reagents.
Tissue culture and transfections
293T cells were cultured in DMEM with 10% fetal bovine serum (Gibco),
Penicillin (100 units/ml)/Streptomycin (100 mg/ml), and L-glutamine (2 mM).  Cells were
split 1:5 prior to the day of transfection and transiently transfected with 40 mg of plasmid.
Cells were 60% confluent in 100 mm dishes on the day of transfection. DNA (20 mg of
pFLAG-Cul1[RDB1347] and 20 mg of pFLAG-b-TRCP[RDB1189]) by calcium phosphate
precipitation. Cells were harvested 30 hours following transfection.   Five micrograms of
pGL-1, a plasmid containing the CMV promoter linked to the green fluorescent protein
(GFP) cDNA was co-transfected  into cells at the same time to assess transfection
efficiency.  In all experiments, greater than 80% of the cells were GFP–positive at the time
of harvest.
Immunoprecipitation and ubiquitination assays
293T cell pellets were lysed with 200 ml of lysis buffer (TrisCl 25 mM, pH 7.5,
NaCl 150 mM, Triton-X100 0.1%, and NaF 5 mM, EGTA 0.05 mM and PMSF 1 mM).
Pellets from cells transfected with vector, pFLAG-b-TRCP or pFLAG-Cul-1 were vortexed
for 10 seconds, then incubated on ice for 15 minutes.  Following centrifugation at 13,000
rpm for 5 minutes at 4oC, the supernatant was added to 20 ml of FLAG M2 beads (Sigma,
Inc.), which were washed with lysis buffer three times prior to immunoprecipitation.
Lysates were incubated with the beads on a rotator for two hours at 4oC, followed by one
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wash with Hepes buffer 25 mM, pH 7.4, Triton-X100 0.01%, and NaCl 150 mM (Buffer
A) and one wash with the same buffer without Triton-X100 (Buffer B).  For binding assays
(Fig. 3), 50% (10 µl) of the 9 µM MetAP-2/50 µM Protac-1 mixture was loaded as input;
the other 50% added to beads.  Following addition of ligand, the beads were rotated at
room temperature for 1 hour.  The beads were washed once each with buffers A and B.
Following centrifugation, half of the bead and supernatant fractions, representing bound
and unbound, respectively, were evaluated by western blotting as described in 'MetAP-
2–Protac-1 coupling assay'.  For ubiquitination reactions, 4 ml of 18 µM MetAP-2, 4 ml of
100 µM Protac-1, 0.5 ml of 0.1 µg/µl purified mouse E1, 1 ml 0.5 µg/µl human Cdc34 E2,
and 1ml 25 mM ATP were added to 20 µl (packed volume) of washed FLAG-M2 beads.
For competition experiments, the phosphopeptide (100 mM final) or ovalicin (100 mM
final) was added simultaneously with the Protac-1. Reactions were incubated for one hour
at 30oC in a thermomixer (Eppendorf) with constant mixing.  SDS-PAGE loading dye was
added to terminate reactions, which were evaluated by western blotting as described in
MetAP-2–Protac-1 coupling assay
The experiments performed herein employed two different preparations of MetAP-2.
One preparation consisted primarily of a 47 kDa fragment that was generated either by a
contaminating protease, or slow autoproteolysis.  The second preparation consisted almost
entirely of full length  67 kDa MetAP-2.  Essentially identical results were obtained with
both preparations.
42
Degradation experiments with Xenopus extracts
Extracts from unfertilized Xenopus laevis eggs were prepared the day of the
experiment.  The MetAP-2-Protac-1 mixture (4 ml of 9 µM MetAP-2 plus 50 µM Protac-1)
or MetAP-2 alone was added to 10 ml of extract in addition to ovalicin (10 mM final), IKK-
EE (0.4 µg) and okadaic acid (10 mM final).  LLnL (50 µM final), epoxomicin (10 µM
final), or DMSO vehicle were added to the indicated concentrations to inhibit degradation
by the proteasome. The protease inhibitors, chymostatin, pepstatin, and leupeptin (15
mg/ml final concentration), were also added to the extracts.  Reactions were incubated for
the indicated timepoints at room temperature and terminated by adding 50 µl of  SDS-
PAGE loading dye.  Samples were evaluated by western blotting as described above.
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Figures
Figure II-1.  Protac-1 targets MetAP-2 to SCF. Protac-1 is a chimeric molecule that consists
of a phosphopeptide moiety and a small molecule moiety that interacts with the protein target
(A).  The synthesis scheme for Protac-1 is shown (B; see Materials and Methods).
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Figure  II- 2. MetAP-2 binds Protac specifically and in a concentration-dependent
manner.
(A): MetAP-2 (9 mM) was incubated with increasing concentrations of Protac-1 at room
temperature for 45 minutes.  The last two lanes depict MetAP-2 that was incubated with
either free IkBa phosphopeptide = IPP (50 mM) or free ovalicin = OVA (50 mM), as
indicated.  Following incubation, samples were supplemented with SDS-PAGE loading
dye, fractionated by SDS-PAGE, and immunoblotted with MetAP-2 antiserum.  (B):Same
as (A), except MetAP-2 (9 mM) plus Protac-1 (10 mM) were supplemented with either
IkBa phosphopeptide (50mM) or ovalicin (50mM) as indicated.  Protac binding to MetAP-2
was inhibited by addition of ovalicin, but not phosphopeptide (B).
MetAP-2
MetAP-2-Protac-1
  0   10pM  10nM  10mM 10mM  
Protac-1
   IPP             -     -    -    -    -    +    -     -     -    +    -    +   -                       
   OVA    
  10mM
Protac-1
A. B.
 0
-     -    -    -    -    -    + -     -    -    +    -   +
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Figure II-3.  Protac-1 recruits MetAP-2 to SCFb-TRCP.
Extracts from 293T cells transiently transfected with either control vector or plasmids
expressing FLAG epitope-tagged Cul1 and b-TRCP were subject to affinity purification on
anti-FLAG resin to yield either control beads or SCFb-TRCP beads.  The matrices were then
mixed with the preformed MetAP-2–Protac-1 complex (input), incubated, and separated
into bound (pellet) and unbound (sup) fractions.  Proteins were fractionated on an SDS-
10% polyacrylamide gel, and immunoblotted with anti-MetAP-2 antiserum.  MetAP-2 and
MetAP-2–Protac-1 refer to free MetAP-2 and MetAP-2 complexed with Protac-1,
respectively.  The 1X and 2X represent the relative amount of E1, E2, and ubiquitin added
to the reactions.
Control beads SCF bTRCP beads
MetAP-2-Protac-1
MetAP-2
input     bound     sup    input     bound     sup 
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Figure II-4.  Protac mediates MetAP-2 ubiquitination by SCF.
(A) Ubiquitination of the 46 kDa fragment of MetAP-2.  MetAP-2–Protac-1 mixture was
added to either control (mock) or SCFb-TRCP beads (+) supplemented with ATP plus
purified E1, E2 (Cdc34), and ubiquitin. UbcH5c (500 ng) was also tested as E2 in the
reaction, which resulted in the same degree of ubiquitination as observed with Cdc34 (data
not shown).  Reactions were incubated for one hour at 30oC, and were evaluated by SDS-
PAGE followed by western blotting with anti-MetAP-2 antiserum.  (B): Ubiquitination of
full length (67 kDa) MetAP-2. Same as (A), except that the 67 kDa preparation of MetAP-
2 was used, and E1, E2, plus ubiquitin were either added at normal (1X) or two-fold higher
(2X) levels, as indicated.  (C): Ubiquitination of MetAP-2 by SCFb-TRCP depends upon
Protac-1.  Same as (A), except that methyl ubiquitin (Me) was substituted for ubiquitin, as
indicated, and the reactions depicted in lanes 5-7 lacked Protac-1.  In lane 7, unlinked IkBa
phosphopeptide (IPP) and ovalicin (OVA) were each added at 100 mM in place of Protac-1.
(D): Protac-1 dependent ubiquitination of MetAP-2 is competitively inhibited by
IkBa phosphopeptide.  Same as (A), except that reactions in lanes 3 and 4 were
supplemented with 100 mM each IkBa phosphopeptide (IPP) and ovalicin (OVA),
respectively.
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Figure II-5.  MetAP-2-Protac is degraded in Xenopus extracts.
The MetAP-2–Protac-1 mixture  or MetAP-2 alone was added to Xenopus egg extract
fortified with ovalicin (OVA; 100 mM), IKK-EE (0.4 µg) and okadaic acid (10 mM).
Where indicated, reactions were either deprived of IKK-EE or okadaic acid (OA), or were
further supplemented with 50 mM LLnL or 10 mM epoxomicin (Epox).  Reactions were
incubated for the indicated timepoints at room temperature, terminated by adding SDS-
PAGE loading dye, and evaluated by SDS-PAGE followed by western blotting with anti-
MetAP-2 antiserum.
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Figure II-6.  General application of Protacs.  A schematic of how different disease-
promoting proteins might be recruited to different ubiquitin ligases for ubiquitination and
degradation by unique Protacs.
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Chapter III
Protacs Target MetAP-2 to the Cbl Ligase for Ubiquitination
The results presented in this chapter were generated in collaboration with Craig Crews and
Ning Zheng. This work has been previously published (Sakamoto K.M., Mol. Gen. Metab.,
2002; see Appendix).
Introduction
The Cbl family of proteins comprises of five known members:  three mammalian
proteins, c-Cbl, Cbl-b, and Cbl 3, and two from invertebrates Sli-1 (C. elegans) and D-Cbl
(D. melanogaster).  There are also two oncogenic forms of Cbl, v-Cbl and 70Z-Cbl.  Sli-1
negatively regulates signaling from a receptor tyrosine kinase (RTK).  All Cbl proteins
have a unique domain that recognizes phosphorylated tyrosine residues that are present on
activated tyrosine kinases.  Cbl proteins also recruit ubiquitin-conjugating enzymes (E2s or
UBCs) to activated RTKs and direct multi-ubiquitinated proteins for degradation  (1).  Cbl
proteins therefore function by specifically targeting activated RTKs and mediating their
downregulation, thereby providing a means by which signaling processes can be negatively
regulated.  Interestingly, Cbl proteins are involved in positive signaling events through its
function as a multidomain adaptor protein that is required for functions associated with
bone resorption, glucose uptake in response to insulin, and cell spreading in response to
integrin engagement  (1).
All of the Cbl proteins share a high degree of sequence similarity in the NH2-
terminal half, which includes a phosphotyrosine-binding (PTB) domain, a short linker
54
region, and the RING domain.  The PTB domain is composed of a four-helix bundle
domain that contains two calcium-binding EF hand motifs, and a domain that adopts the
fold of classical Src homology 2 (SH2) domains but has very little sequence similarity to
other SH2 domains.  The four-helix, EF hand, and SH2 domains all contribute to the PTB
function.  The COOH-terminal halves of c-Cbl and Cbl-2 contain proline-rich regions,
which serve as docking sites for Src homology 3 (SH3) domain-containing proteins, such
as growth receptor binding protein 2 (Grb2), Src, and phosphatidylinositol 3-kinase (PI3K),
and several tyrosines, which, when phosphorylated by activated tyrosine kinases, bind to
the SH2 motifs of various signaling molecules.  Finally c-Cbl forms homodimers through
the leucine zipper at the very COOH terminal of the protein (1).
Although c-Cbl and Cbl-b-deficient mice are generally healthy and do not show
developmental abnormalities, they have a marked defect in thymocyte and peripheral T-cell
activation, respectively.  Thymocytes in c-Cbl-/- mice show a marked activation of ZAP-70
in response to T cell receptor activation compared to wild type thymocytes.  The  Cbl-b
deficient mice are highly susceptible to autoimmune disease.  Thus a lowered threshold for
TCR signaling is a common theme in both mutant mice (1).
C-Cbl was identified through the isolation of the oncogenic v-Cbl protein
consisting only of the TKB domain.  V-Cbl appears to function as a dominant-negative
protein by competing with wild-type Cbl proteins for binding sites on activated tyrosine
kinases, thus preventing Cbl from negatively regulating these target kinases.  This model is
supported by the inability of v-Cbl to transform when its TKB domain is mutated (G306E)
and can no longer bind activated tyrosine kinases.  A mutant form of c-Cbl was isolated
from the 70Z/3 mouse pre-B cell lymphoma cells.  This mutant protein, called 70Z-Cbl, has
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a 17-amino-acid deletion between 366 and 382 that removes most residues in the linker
domain that encompass the a-helix, plus the first cysteine of the RING finger.  Expression
of a Cbl protein with this 17-amino-acid deletion, or deletion of either of two tyrosine
residues within the a-helix of the linker induces more rapid and acute transformation of
NIH 3T3 cells than does v-Cbl (1,2).
Recently, the structure of the complex between c-Cbl and the E2 UBCH7 has been
elucidated (3, 4).  Furthermore, the ZAP-70 phosphopeptide and recognition site of Cbl
were determined and found to be evolutionarily conserved (5, 6).  Based on the crystal
structure of the c-Cbl/UbcH7/phospho-Zap-70 peptide complex, the linker interacts with
both UbcH7 and the TKB domain of c-Cbl and thus its mutations may disrupt both E2-
dependent activity and PTK-binding ability of c-Cbl.
To test the concept of Protac in a more generalizable manner, we sought to use c-
Cbl as another ubiquitin ligase in place of SCFb-TRCP.  A Protac was generated consisting of
the minimal ZAP-70 phosphopeptide and the MetAP-2 binding protein, ovalicin.  We first
tested whether  the Zap-70-ovalicin Protac could inhibit ubiquitination of a known
substrate of c-Cbl.  Next, we determined whether MetAP-2 binds Zap-70-ovalicin Protac in
a specific, concentration dependent manner.  Finally, we performed experiments that would
demonstrate that c-Cbl ubiquitinates MetAP-2 in the presence of Zap-70-ovalicin Protac.
Results
Zap-70-ovalicin inhibits Cbl ligase activity
A Protac containing a Zap-70 phosphopeptide at one end and ovalicin moiety at
the other end was generated to test whether MetAP-2 could be recruited to Cbl for
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ubiquitination.  We first tested whether the Zap-70-ovalicin could inhibit ubiquitination of
a known substrate of Cbl, “X”.  Increasing concentrations of Protac and the Zap-70
phosphopeptide alone inhibited the ubiquitination of substrate “X” (Fig. 1).  However, the
concentration of Protac (100 mM) required to inhibit ubiquitination of “X” was higher than
the concentration (10 mM) required for IkBa phosphopeptide or Protac to inhibit IkBa
ubiquitination.  Therefore, the Zap-70 phosphopeptide and Protac specifically inhibits the
ubiquitination of a known substrate of Cbl in a concentration-dependent manner.
MetAP-2 specifically binds Zap-70-ovalicin Protac in vitro
To demonstrate that purified MetAP-2 bound Zap-70 Protac,  we incubated MetAP-2
(18mM) with increasing concentrations of Protac (Fig. 2).  A Western blot analysis was
performed with anti-MetAP-2 anti-serum.  At 200 mM Protac and above, we observed two
bands; the lower band represents unbound MetAP-2, and the upper band represents MetAP-
2 bound to Protac.  Addition of Protac at higher concentrations yielded a third band that is
possibly a result of dimerization of MetAP-2.  Combining MetAP-2 with either free Zap-70
phosphopeptide or free ovalicin did not yield the doublet observed with the Protac.  We also
tested the specificity of MetAP-2 interaction with Protac in vitro.  Free ovalicin, but not free
Zap-70 phosphopeptide, inhibited the formation of the MetAP-2 Protac complex.
Therefore, our results demonstrate that MetAP-2 was specifically conjugated to the ovalicin
moiety of Protac in a concentration-dependent manner.
Zap-70-ovalicin Protac mediates the ubiquitination of MetAP-2
To test whether Protac mediates MetAP-2 ubiquitination by Cbl, we performed
experiments with MetAP-2, Cbl, ubch4 (E2), and several E1s, including GST-E1, yeast E1
and Rabbit UBA1 (Boston Biochem, Inc.).  MetAP-2 was ubiquitinated by Cbl in a Protac-
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dependent manner (Fig.  3).  In the absence of Protac, we did not observe modification of
MetAP-2.  These results demonstrated that the Zap-70-ovalicin recruited MetAP-2 to Cbl,
resulting in ubiquitination.  Therefore, Protacs can be generalized to target proteins to
ubiquitin ligases other than SCFb-TRCP.
Discussion
The goal of these experiments was to further test our hypothesis that a chimeric
molecule could recruit and target a stable protein not previously known to be a substrate of
a ubiquitin ligase could be deliberately ubiquitinated.  We showed in Chapter II that
MetAP-2 could be ubiquitinated by the SCFb-TRCP ubiquitin ligase.  In this chapter, we
hoped to determine whether  the ubiquitin ligase Cbl could also ubiquitinate MetAP-2 in
the presence of the chimeric molecule or Protac (Protac).  Our previous results showed that
SCFb-TRCP is a promiscuous enzyme that is able to ubiquitinate MetAP-2 (7).  In this
Chapter, we observed that Cbl could also ubiquitinate a “foreign” protein that is not known
to be a substrate.  However, we observed that the Zap-70-phosphopeptide and the Protac
had decreased affinity for Cbl compared to the previous Protac-1 for SCFb-TRCP described in
chapter II.   Furthermore, the affinity of the Zap-70-ovalicin Protac for MetAP-2 was lower
than the IkBa-ovalicin Protac-1.  These results suggest that certain Protacs may function
better than others, depending on the ligase and the target, requiring further optimization.
We also observed that Cbl could ubiquitinate MetAP-2  in the presence of different E1,
including GST-E1, Rabbit UBA1, and Yeast E1.  Future studies will focus on employing
Protacs to target different proteins as substrates of ubiquitin ligases.  Chapter IV addresses
whether Protacs recruit proteins that associate through noncovalent interactions in vitro and
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in vivo.  Ultimately, our goal is to develop a repertoire of Protacs that will bind to desired
disease-promoting protein for ubiquitination and degradation in tumor cells.
Experimental Procedures
Synthesis of Zap70-ovalicin Protac
Ovalicin (1.4 mmol) was dissolved in 10 mL of methanol at 0 oC and NaBH4 (3.0
mmol) was added slowly. After 30 min stirring, methanol was removed under reduced
pressure and the resulting crude product was purified by flash column chromatography to
yield ovalicinol (1.15 mmol, 82 %). To the ovalicinol, Fmoc-Gly was coupled to give
Fmoc-Gly-ovalicinol.  Specifically, dimethylformamide (DMF) (28 µL) was added to
dichloromethane solution (30 mL) containing Fmoc-Gly-OH (3.56 mmol) and oxalyl
chloride (7.12 mmol) at 0 oC.  After 3 hour stirring at room temperature, dichloromethane
was removed under nitrogen atmosphere. The resulting solid residue was redissolved in
dichloromethane (10 mL) and was combined with ovalicinol (0.6 mmol) and
dimethylamino pyridine (DMAP) (4.7 mmol) in dichloromethane (30 mL) at 0 oC.  The
reaction mixture was stirred for 2 hours at room temperature.  After dichloromethane was
removed under reduced pressure, the resulting residue was flash chromatographed to
provide Fmoc-Gly-ovalicinol (0.39 mmol, 65 %). Next, Fmoc-Gly-ovalicinol (0.09 mmol)
was treated with 20 % piperidine in DMF (2 mL) at room temperature for 10 minutes and
DMF was removed under high vacuum. The resulting solid was redissolved in 2 mL of
dimethylsulfoxide (DMSO) and disuccinimidyl suberate (DSS) (0.9 mmol) was added at
room temperature. After overnight stirring, DMSO was removed under high vacuum and
the resulting crude product was flash chromatographed to give monosuccinimidyl suberate-
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Gly-ovalicinol (0.06 mmol, 68 %). Monosuccinimidyl suberate-Gly-ovalicinol (12 µmol)
in DMSO (0.6 mL) was added to DMSO solution (1 mL) containing Zap70 peptide (3.67
µmol) and DMAP (11 µmol). After 20 min stirring at room temperature, the coupling
reaction was completed, which was confirmed by Kaiser test. DMSO was removed under
high vacuum and the resulting crude product was repeatedly washed with dichloromethane
and methanol to remove excess monosuccinimidyl suberate-Gly-ovalicinol to give the final
product (Zap70 peptide-suberate-Gly-ovalicinol) (5.8 mg, 2.59 µmol, 70 %). The final
product was characterized by electrospray (ES) mass spectrometry.  ES-MS (M+H)+ for
ovalicinol-Gly-suberate-Zap70 peptide:DMAP, 2,231.56. All other intermediates were
characterized by 500 MHz 1H NMR spectroscopy.
MetAP-2–Protac-1 coupling assay
MetAP-2 (9 mM) was incubated with increasing concentrations of Protac
(dissolved in water) at room temperature for 45 minutes.   Reactions were supplemented
with SDS loading dye, fractionated on a 10% SDS-polyacrylamide gel, transferred onto a
nitrocellulose membrane and immunoblotted with rabbit polyclonal anti-MetAP-2
antiserum (Zymed, Inc.).  ECL was performed using Amersham detection reagents.
Ubiquitination assays
For experiments with Cbl ubiquitination of “X” in the presence of  Zap70
phosphopeptide as competitor, “X” was phosphorylated in the presence of 32PgATP at
37oC for 30 minutes and added to reaction with E1, E2, and Cbl.  For ubiquitination
reactions, 4 ml of 18 µM MetAP-2 preincubated with 4 ml of 100 µM Protac, 0.5 ml of 0.1
µg/µl purified rabbit, yeast or GST-E1 1 ml, 0.5 µg/µl ubch4 E2, and 1ml 25 mM ATP were
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added to 10 ml (packed volume) of purified Cbl (kindly provided by Ning Zheng).  For
competition experiments, the phosphopeptide (100 mM final) or ovalicin (100 mM final)
was added simultaneously with the Protac-1. Reactions were incubated for one hour at
30oC.  SDS-PAGE loading dye was added to terminate reactions, which were evaluated by
western blot analysis.
Acknowledgements
I would like to thank Rati Verma for helpful suggestions, Craig Crews for
providing the Protacs, and Ning Zheng for providing purified Cbl, ubch4, and GST-E1 for
ubiquitination assays.  This work was supported by CaPCURE and the UC BioSTAR
Project (biostar 01-10232).  I would also like to thank Frank Mercurio and Celgene, Signal
Research Division for supporting this work and providing reagents.
61
Figures
Figure III-1.  The Zap-70-ovalicin Protac (Protac) and Zap-70 phosphopeptide inhibit
ubiquitination of Cbl substrate “X.” “X” was phosphorylated with kinase in the presence of
32Pg ATP, then incubated with Cbl, ubch4, ubiquitin, and Protac or phosphopeptide.  These
results demonstrate that the Zap-70 Protac inhibits Cbl ubiquitination of  “X.”
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Figure III-2.  MetAP-2 binds Zap-70-ovalicin Protac (PTCM=Proteolysis Targeting
Chimeric Molecule) specifically in a concentration-dependent manner.  MetAP-2 (9 mM)
was incubated with increasing concentrations of Protac at room temperature for 45 min.  The
last two lanes on the right depict MetAP-2 that was incubated with either free Zap-70
phosphopeptide or free ovalicin.  Protac binding to MetAP-2 was inhibited by the addition of
ovalicin, but not by the addition of the Zap-70 phosphopeptide.
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Figure III-3.  Ubiquitination of MetAP-2 by Cbl. MetAP-2 bound to Zap70 phosphopeptide-
ovalicin was added to purified Cbl, with E1, and E2 (Ubch4), and ubiquitin (ub). The reaction
was incubated for 30 minutes at room temperature. Western blot analysis was performed with
anti-MetAP-2 antisera.  These results suggest that Protac technology can be applied to other
ubiquitin ligases.
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Chapter IV
Development of Protacs to Target Cancer-Promoting Proteins for Ubiquitination and
Degradation
The data presented in this chapter were generated in collaboration with Kyung B. Kim, Rati
Verma, Andy Ransick, Bernd Stein, and Craig M. Crews.  This work was previously
published (Sakamoto et al., 2003; Appendix).
Introduction
One of the major pathways to regulate protein turnover is ubiquitin-dependent
proteolysis.  Post-translational modification of proteins with ubiquitin occurs through the
activities of ubiquitin activating enzyme (E1), ubiquitin-conjugating enzymes (E2), and
ubiquitin ligases (E3), which act sequentially to catalyze the attachment of ubiquitin to
lysine residues in an energy-dependent manner  (1,2).  Among the hundreds of E3s
encoded within the human genome, the SCF ubiquitin ligases comprise a heterotetrameric
group of proteins consisting of Skp-1, Cul1, a RING-H2 protein Hrt1 (also known as Roc1
or Rbx1) and an F-box protein (1,3).  The mammalian F-box protein b-TRCP of SCFb-TRCP
binds  IkBa, the negative regulator of NFkB, and promotes its ubiquitination and
degradation  (4).  A 10-amino-acid phosphopeptide segment of IkBa is both necessary and
sufficient to mediate its binding to SCFb-TRCP and subsequent ubiquitination and
degradation (4).
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There is a pressing unmet need to develop effective drugs to treat cancer and other
diseases that afflict humans.  The recent completion of the human genome sequence
coupled with basic studies in molecular and cellular biology have revealed hundreds to
thousands of proteins that could conceivably serve as targets for rational drug therapy.
Unfortunately, many of these protein targets are not considered to be readily “drugable”, in
that they are not enzymes and it is not obvious how to inhibit their function with small
molecule drugs.  Thus, it would be valuable to have a generic method that would enable
specific and efficacious inhibition of any desired protein target, regardless of its
biochemical function.  Short interfering RNA (siRNA) represents one such method (5, 6),
but it remains unclear whether siRNA will work as therapeutic agents in humans.  We
sought to develop a different approach, taking advantage of the 10-amino acid
phosphopeptide sequence of IkBa described above to target proteins for ubiquitination and
degradation (4).
67
As proof of concept, we previously synthesized a chimeric molecule or Protac
(Proteolysis Targeting Chimeric molecule) consisting of the IkBa phosphopeptide linked
to ovalicin, which covalently binds methionine aminopeptidase-2 (Met-AP-2). We showed
that this Protac (Protac-1) recruits MetAP-2 to the SCFb-TRCP ubiquitin ligase resulting in
both ubiquitination and degradation of Met-AP2 (7).  MetAP-2 is not known to be an
endogenous substrate of SCFb-TRCP (8), and was not ubiquitinated by SCFb-TRCP in the
absence of Protac-1.  Although this experiment demonstrated that Protacs could work as
envisioned, it left open a number of critical questions.  For example, can Protacs be used
more generically to target other substrates, including proteins of potential therapeutic
interest?  Can a Protac recruit a target to SCFb-TRCP through a noncovalent interaction?  Can
a Protac work within the context of a cell?
Both estrogen receptor alpha (ERa) and androgen receptor (AR) have been
demonstrated to promote the growth of breast and prostate cancer cells (9, 10).  In fact,
there are several treatment modalities such as Tamoxifen and Faslodex, which control
breast tumor cell growth through inhibition of ER activity.  In early prostate cancer, tumor
cells are often androgen-responsive.  Patients with prostate cancer receive hormonal
therapy to control tumor growth.  Recent evidence suggests that even in androgen-
independent prostate cancer, the AR may promote tumor growth  (10).  Similarly, many
tamoxifen-resistant tumors still express ER (11).  Thus, new drugs that downregulate AR
and ER by novel mechanisms may be of potential benefit in treating breast and prostate
cancers.
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To address the key questions about Protacs raised by our first study, we set out to
develop Protacs comprising the IkBa phosphopeptide linked to either estradiol or
dihydroxytestosterone (DHT) to recruit ER or AR to SCFb-TRCP to accelerate their
ubiquitination and degradation.  Recently, both the ER and AR have been shown to be
regulated by proteasome-dependent proteolysis (12-14).  We reasoned that Protacs might
mimic the action of the human papillomavirus E6 protein, which accelerates the turnover of
the already unstable p53 to the point where p53 can no longer accumulate, resulting in loss
of its function (15).
In this paper, we report the feasibility of using Protacs to target degradation of
proteins known to promote tumor growth.  We show that Protacs can recruit the ER for
ubiquitination and degradation in a cell-free system.  Furthermore, our results demonstrate
that in cells, Protacs can promote the degradation of AR in a proteasome-dependent
manner.  Thus, Protacs may be a useful therapeutic approach to destroy proteins that
promote tumor growth in patients with cancer.
Results
Protacs consisting of the minimal 10 amino acid peptide (phosphorylated on the
underlined S residues), DRHDSGLDSM covalently linked to either estradiol (E2; Protac-2)
or dihydroxytestosterone (DHT; Protac-3) were synthesized (Fig. 1).  We first performed in
vitro ubiquitination assays with both Protacs, but focused our efforts on Protac-2 due to
problems encountered with expression of recombinant AR.  To determine whether Protac-2
promotes the ubiquitination of ER by SCFb-TRCP in a concentration-dependent manner, we
performed ubiquitination assays with increasing concentrations of Protac (Fig. 2A).  ER
69
was ubiquitinated starting at a concentration of 0.1 to 1mM Protac-2, with maximal
efficiency observed at 5mM to 10mM.  At 500 mM, we no longer observed ubiquitination of
ER by SCFb-TRCP, which may be due to a ‘squelching’ phenomenon wherein the presence
of excess Protac-2 inhibits competitively the formation of heteromeric ER–Protac-2–SCF
complexes.  Since 10 mM Protac-2 promoted efficient ubiquitination of ER, we continued
to use this concentration for the remainder of our studies (except as noted below).  It should
be noted that we consistently observed Cul1-dependent ubiquitination of ER in the absence
of Protac-2 (e.g., Fig. 2A and 2B, lane 1).  This may be due to the presence of an ER-
specific SCF ubiquitin ligase in the Cul1 precipitates.  Regardless, these Protac-
independent conjugates were of low molecular weight and clearly distinguishable from the
high molecular weight, methyl ubiquitin-sensitive conjugates induced by Protac-2 (e.g.,
compare lanes 1, 3, and 4 of Fig. 2B).
To address the mechanism of action of Protac-2, we tested whether the IkBa
phosphopeptide and estradiol individually can compete out Protac-2, and whether these
ligands when added together as free compounds can mimic the action of Protac-2.  A 10-
fold excess of either IkBa phosphopeptide (Fig. 2D) or estradiol (Fig. 2E) in cells
completely blocked the ubiquitination-promoting activity of 1mM Protac-2.  Moreover,
when added together as separate compounds, estradiol and IkBa phosphopeptide failed to
reproduce the effect of Protac-2 (Fig. 2C).
These results are consistent with our hypothesis that Protac-2 acts as a bridging
molecule in that the estradiol moiety associates with the ER while the other moiety, the
IkBa phosphopeptide, recruits the ER to the SCFb-TRCP.
70
We next tested the specificity of Protac-mediated ubiquitination.  Ubiquitination
assays with ER were performed in the presence of either Protac-2, Protac-3 or a Protac
(Protac-4) that consisted of the Zap70 phosphopeptide, which is recognized by the Cbl
ubiquitin ligase (16) and ovalicin, which binds Met-AP-2 (8).  As shown in Fig. 2F, ER
was not ubiquitinated by SCFb-TRCP in the presence of either Protac-3 or Protac-4.
Not all ubiquitin-ubiquitin linkages are able to sustain targeting to the proteasome (17), and
possibly as a consequence, substrates ubiquitinated under the relatively artificial conditions
encountered in reconstituted systems can be poor substrates for the proteasome (18).  Thus,
we sought to determine whether ER-ubiquitin conjugates induced by Protac-2 were
recognized by the 26S proteasome.  To answer this question, purified yeast 26S proteasome
(19) was added to ubiquitinated ER formed in the presence of SCFb-TRCP and Protac-2.
Complete disappearance of high MW ubiquitin conjugates was observed within 10 minutes
(Fig. 3A) and was partially blocked by the metal chelator 1,10 phenanthroline (which
inhibits the essential Rpn11 isopeptidase activity of the proteasome), but not by the inactive
derivative 1,7 phenanthroline (20) (Fig. 3B).
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Our results with the IkBa phosphopeptide-estradiol Protac demonstrated that a
medically relevant target protein can be recruited to a ubiquitin ligase through noncovalent
interactions and be ubiquitinated and degraded in vitro.   We next wished to test whether a
Protac could promote the degradation of proteins in cells.  For these experiments we used
Protac-3, because we encountered technical difficulties in working with cells that
transiently expressed an ER-based reporter protein and because a 293 cell line that stably
expresses AR-GFP (293AR-GFP) was readily available to us.  We employed microinjection
because the phosphate groups on the IkBa phosphopeptide preclude its efficient uptake into
cells.  293AR-GFP cells were injected with Protac-3 (10 mM stock; 1mM final) and monitored
for presence or absence of GFP by fluorescence microscopy.  A time course was
performed, and maximal GFP-AR degradation was observed one hour after injection of
Protac (data not shown; Fig. 4A).  We observed that the majority of cells injected with
Protac expressed decreased levels of GFP (Fig. 4B).  This decrease was not due to GFP-AR
leakage since cells coinjected with rhodamine were not affected after one hour (indicated
by the pink stained cells shown in Fig. 4).  To quantify the degree of GFP-AR degradation,
we counted over 200 cells and determined the relative decrease in GFP-AR signal one hour
following injection (Fig. 4B).  Greater than 70% of cells demonstrated minimal, partial, or
complete disappearance of GFP-AR. In all experiments, only cells that continued to be
rhodamine positive after one hour were counted.  Each experiment was performed on at
least two separate days with 30-50 cells injected per experiment.  Injection of rhodamine or
200 mM KCl buffer alone did not result in disappearance of GFP from 293AR-GFP cells (data
not shown).
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We further verified that the linkage of phosphopeptide and DHT was required for
GFP-AR degradation.  Coinjection of free IkBa phosphopeptide and testosterone (10mM
each) into 293 cells did not result in decreased GFP signal (Fig. 4C), indicating that intact
Protac is necessary to promote degradation of GFP-AR.  To determine whether GFP-AR
degradation was dependent on IkBa phosphopeptide and testosterone binding to their
respective targets, we coinjected Protac-3 (10mM) with a 10-fold molar excess (100mM)
of free phosphopeptide (Fig. 4D) or testosterone (Fig 4E) into 293AR-GFP cells.  In both
cases, degradation of GFP-AR was inhibited.   All experiments were performed on 3
separate days with 20 to 30 cells injected per experiment.  The results shown are
representative of the phenotype in greater than 70% of cells counted.  Taken together, these
data support the hypothesis that Protac-3 induced AR-GFP degradation by targeting AR-
GFP to SCFb-TRCP.
To determine whether the disappearance of GFP-AR was proteasome dependent,
293AR-GFP cells were treated with the proteasome inhibitor epoxomicin for 4 hours prior to
injection with Protac-3 (10 mM)(Fig. 4F).  In cells treated with epoxomicin, GFP-AR was
not degraded, suggesting that the Protac mediates degradation through a proteasome-
dependent pathway.  Cells were also coinjected with Protac (10mM) and epoxomicin
(10mM) in the absence of pretreatment resulting in inhibition of GFP-AR degradation (data
not shown).  The result shown is representative of experiments performed on three different
days with at least 30 cells injected per day.
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As demonstrated previously (Fig. 2F), the IkBa phosphopeptide-estradiol Protac-2,
but not Protac-3, specifically induces ubiquitination of ER in vitro.  The specificity is
dependent on the ability of Protac-2 to be recognized by the ubiquitin ligase as well as its
ability to bind to ER.  The same specificity of Protac action appears to hold true in cells,
because Protac-2, unlike Protac-3, does not induce degradation of GFP-AR (Fig. 4G)
Discussion
The ubiquitin-proteasome pathway rapidly, efficiently, and selectively ubiquitinates
and degrades targeted polypeptides.  Many signaling processes critical to the biology of
normal and diseased cells are regulated by ubiquitin-dependent proteolysis, including exit
from M phase of the cell cycle and initiation of innate immune response, which are
respectively controlled by degradation of cyclin B and the NF-kB regulator IkBa (21, 22).
To harness the power of the ubiquitin-proteasome pathway for therapeutic purposes, we are
developing ‘Protacs’ to recruit proteins to ubiquitin ligases to promote their ubiquitination
and degradation.  An important aspect of the Protacs approach is that it in theory can be
applied to any protein in the cytoplasm or nucleus of a diseased cell, and thus may enable
the development of therapeutics against a large fraction of proteins in the proteome.  The
linchpin of our approach is a heterobifunctional small molecule (i.e., Protac) that serves as
a bridge to link a target protein to a ubiquitin ligase. Previously, we demonstrated that a
Protac comprising a phosphopeptide that binds SCFb-TRCP and a small molecule (ovalicin)
that binds MetAP-2 activates the ubiquitination of MetAP-2 by SCFb-TRCP ubiquitin ligase
in vitro, and consequently targets MetAP-2 for degradation by the proteasome in frog
extract (7).
74
Our goals in the current work were to show that Protacs can increase the turnover of
a given target protein in cells, and to extend the Protacs approach to proteins that play a
causal role in human diseases.  We chose the estrogen and androgen receptors for our
current studies due to their well-characterized association with estrogen and androgen,
respectively.  Furthermore, both receptors have been associated with the development and
progression of cancer.
The results reported here indicate that Protacs operate by a bridging mechanism to
enable efficient and specific downregulation of ER in vitro and AR in cells.  From our in
vitro data, it is apparent that Protacs can be developed against different targets (MetAP-2,
ER, and AR), and that Protacs promote ubiquitination of these targets in a manner that is
both target-selective and dose-dependent.
From microinjection experiments, it is clear that Protacs can activate AR turnover
in the context of the cellular degradation machinery.  This degradation was also found to be
specific and dependent on both components of the Protac molecule.  Moreover the
proteasome inhibitor epoxomicin blocked the ability of Protacs to promote AR turnover,
suggesting that the degradation is proteasome-specific and not due to alternative pathways,
such as those involving lysosomes, or due to other proteases, such as caspases.
75
To deliver Protacs to cells in the experiments described here, we employed
microinjection due to the impermeability of the SCFb-TRCP-binding IkBa phosphopeptide
moiety.  A key remaining challenge for Protac technology is to develop cell permeable
molecules that can be used to test for efficacy in cell and animal models of cancer.
Ongoing work in our laboratories suggests that Protacs based on the hydroxyproline motif
of HIF1-a may be used to target ubiquitination and degradation of proteins in cells through
the VHL ubiquitin ligase pathway (manuscript in preparation).
We postulate that many Protac compounds can be generated to treat a variety of
diseases.  First of all, hundreds of putative ubiquitin ligases that can be exploited as agents
of Protac action have been  uncovered by the Human Genome Project.  Second, it is
important to note that Protacs should not be limited to receptors with well-defined ligands
such as AR and ER. In theory, any protein that binds a small molecule through high affinity
interactions can be a candidate target.  Our studies suggest that Protacs technology is not
only feasible, but warrants further exploration as an alternative to conventional
pharmacologic inhibition of proteins that promote human disease.  Current treatment of
cancer includes drugs that nonspecifically inhibit the cell cycle, DNA repair, and
metabolism.  Protacs provide a means of specifically targeting a protein that is known to
regulate abnormal growth and survival of cancer cells, in much the same way that Gleevec
improves the survival of CML patients by inhibiting the causative agent BCR-ABL (23).
The hope is that by developing a generic method that enables us to target the proteins
responsible for the malignant phenotype, regardless of their mechanism of action or
functional attributes, it will be possible to combat cancer while sparing damage to normal
cells.
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Experimental Procedures
Synthesis of Protacs
IkBa phosphopeptide-estradiol Protac. To generate GA-1-monosuccinimidyl
suberate, the estradiol derivative, GA-1 , (7 mg, 11.5 µmol) was dissolved in 1 ml of
anhydrous DMF, and disuccinimidyl suberate (21 mg, 57.0 mmol) was added at room
temperature. After overnight stirring, DMF was removed under high vacuum, and the
resulting white solid was flash-chromatographed to give GA-1-monosuccinimidyl
suberate (6.3 mg, 7.3 µmol, 63.5 %). For synthesis of GA-1-IkBa phosphopeptide, GA-
1-monosuccinimidyl suberate (6 mg, 6.9 mmol) in DMSO (1 ml) was added to DMSO
solution (0.4 ml) containing IkBa phosphopeptide (1.5 mg, 0.92 mmol) and
dimethylaminopyridine (0.5 mg). After 30 min stirring at room temperature, the coupling
reaction was completed, which was confirmed by a Kaiser test. DMSO was removed
under high vacuum, and the resulting crude product was repeatedly washed with
dichloromethane and methanol to remove excess GA-1-monosuccinimidyl suberate to
give the final product, GA-1-IkBa phosphopeptide (1.5 mg, 0.63 mmol, 68.5%). The
final product was characterized by electrospray (ES) mass spectrometry. ES-MS
(M + H)+ for GA-1-IkBa phosphopeptide was 2384.0 Da. All other intermediates were
characterized by 500-MHz 1H NMR spectroscopy.   
IkBa-DHT Protac. For DHT-Gly-monosuccinimidyl suberate, dimethylformamide
(DMF, 28 µl, 0.33 mmol) was added to dichloromethane solution (20 ml) containing Fmoc-
Gly-OH (1.06 g, 3.57 mmol) and oxalyl chloride (0.62 mL, 7.10 mmol) at 0°C. After 3 hr
of stirring at room temperature, dichloromethane was removed under nitrogen atmosphere.
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The resulting solid residue was redissolved in dichloromethane (8 ml) and was combined
with 5a-dihydrotestosterone (0.18 g, 0.62 mmol) and dimethylaminopyridine (0.58 g,
4.75 mmol) in dichloromethane (20 ml) at 0°C. The reaction mixture was stirred overnight
at room temperature. After dichloromethane was removed under reduced pressure, the
resulting residue was flash-chromatographed to provide DHT-Gly-Fmoc (0.21 g, 0.37
mmol, 60%). Next, DHT-Gly-Fmoc (0.12 g, 0.21 mmol) was treated with
tetrabutylammonium fluoride (TBAF, 0.3 mL, 1M in THF) at room temperature for
20 minutes, and the DMF was removed under high vacuum. The resulting residue was
flash-chromatographed to provide DHT-Gly-NH2 (white solid, 49 mg, 0.14 mmol, 67%).
Next, disuccinimidyl suberate (0.27g, 0.73 mmol) was added to DMF solution (1 mL)
containing DHT-Gly-NH2 (49 mg, 0.14 mmol) at room temperature. After overnight
stirring, DMF was removed under high vacuum, and the resulting crude product was flash-
chromatographed to give DHT-Gly-monosuccinimidyl suberate (70 mg, 0.12 mmol, 86%).
DHT-Gly-monosuccinimidyl suberate (5.5 mg, 9.16 mmol) in DMSO (0.6 ml) was added
to DMSO solution (1 ml) containing IkBa phosphopeptide (4.5 mg, 2.75 µmol) and
dimethylaminopyridine (2.0 mg, 16.37 mmol). After 20 minutes of  stirring at room
temperature, the coupling reaction was completed, which was confirmed by a Kaiser test.
DMF was removed under high vacuum, and the resulting crude product was repeatedly
washed with dichloromethane and methanol to remove excess DHT-Gly-monosuccinimidyl
suberate to give the final product, DHT-IkBa phosphopeptide (3.5 mg, 1.65 mmol, 60%).
The final product was characterized by electrospray (ES) mass spectrometry. ES-MS
(M + H)+ for fumagillol-Gly-suberate-HIF-1a octapeptide was 2,120 Da. All other
intermediates were characterized by 500-MHz 1H NMR spectroscopy.
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Tissue culture and transfections
293T cells were cultured in DMEM with 10% (vol/vol) FBS (GIBCO), penicillin
(100 units/ml), streptomycin (100 mg/ml), and L-glutamine (2mM).  Cells were split 1:5
the day prior to transfection and transiently transfected with 40 mg of plasmid.  Cells were
70% confluent in 100-mm dishes on the day of transfection.  Cells were transfected with
DNA [20 mg of pFLAG-Cul1 (RDB1347) and 20 mg of pFLAG-b-TRCP (RDB1189)]
using calcium phosphate precipitation method as described (7).  Cells were harvested 30
hours after transfection.  Five micrograms of pGL-1, a plasmid containing the
cytomegalovirus (CMV) promoter linked to the green fluorescent protein (GFP) cDNA,
was cotransfected into cells at the same time to assess transfection efficiency.  Cells were
greater than 80% GFP positive at the time of harvesting.
Ubiquitination assays with ER
293T cell pellets were lysed with 200 ml of lysis buffer (25 mM Tris-Cl, pH
7.5/150mM NaCl/0.1% Triton X-100/5mM NaF/0.05 mM EGTA/1mM PMSF).  Pellets
from cells transfected with vector, pFLAG-b-TRCP, or pFLAG-Cul-1 were vortexed for 10
sec, then incubated on ice for 15 minutes.  After centrifugation at 13,000 rpm in an
Eppendorf microfuge for 5 minutes at 4oC, the supernatant was added to 20 ml of FLAG
M2 beads (Sigma), which were washed with lysis buffer three times before
immunoprecipitation.  Lysates were incubated with the beads on a rotator for 2 hours at
4oC, followed by one wash with buffer A (25mM Hepes buffer, pH 7.4/0.01% Triton X-
100/150mM NaCl) and one wash with buffer B (the same buffer without the Triton X-100).
Ubiquitination assay was performed by mixing rabbit E1 (0.2 mg) the E2, Ubch5a (0.8 mg;
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from Boston Biochem), ubiquitin (5 mg) or methyl ubiquitin (1.5 mg), Protac (10 mM final
concentration unless otherwise specified), recombinant ER (260 ng; from Invitrogen, Inc),
and ATP (1mM final concentration) in total reaction volume of 5.0 ml, which was then
added to 20 ml (packed volume) of washed FLAG-M2 beads (102).  Reactions were
incubated for 1 hour at 30oC in a thermomixer (Eppendorf) with intermittent mixing.
SDS/PAGE loading buffer was added to terminate the reactions.  Western blot analysis was
performed by standard methods using polyclonal anti-ER antisera (1:1000 dilution).
Degradation experiments with purified yeast 26S proteasome
 Ubiquitination assays were performed as described above.  Purified 26S yeast
proteasomes (40 ml of 0.5 mg/ml) were added to the ubiquitinated ER on beads and the
reaction was supplemented with 6 ml of 1 mM ATP, 2 ml of 0.2M magnesium acetate, and
ubiquitin aldehyde 5 mM final concentration as previously described (19, 20).  The reaction
was incubated for 10 minutes at 30oC with occasional shaking in a thermomixer. For
proteasome inhibition studies, purified yeast 26S preparations were preincubated 45
minutes at 30oC with the metal chelators 1,10 phenanthroline or 1, 7 phenanthroline
(Sigma) at 1mM final concentration prior to adding to ubiquitinated ER.
Microinjection experiments
293 cells were transfected with a plasmid that expresses GFP-AR (kindly provided
by Charles Sawyers, Howard Hughes Medical Institute, UCLA) as described above.  Cells
were selected with G418 (600 mg/ml) and cultured in MEM with penicillin, streptomycin,
and L-glutamine.  Prior to experiments, cells were approximately 60% confluent in 6 cm
dishes. Protac diluted to 10 mM in KCl (200 mM) with rhodamine dextran (MW 10,000
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Da; 50 mg/ml) was injected into cells through a microcapillary needle using a pressurized
injection system (Picospritzer II).   The injected volume was 0.2pl, representing 5-10% of
the cell volume. For proteasome inhibition experiments, cells were treated with 10 mM
epoxomicin (Calbiochem) for 4 hours or coinjected with epoxomicin (10 mM) and Protac
(10 mM). Photographs were taken following injection using a Nikon 35 mm camera. GFP
and rhodamine fluorescence were visualized with a Zeiss fluorescent microscope.
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Figure IV-1. Protacs to target the ER and AR for ubiquitination and degradation.
(A): Protacs consisting of the IkBa phosphopeptide and either (B): estradiol (E2) or (C):
dihydroxytestosterone (DHT) were synthesized to recruit the ER and AR, respectively, to
the SCFb-TRCP ubiquitin ligase.
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Figure IV-2. Protac-2 activates ubiquitination of ER in vitro.   (A): dose-dependent
stimulation of ER ubiquitination by Protac-2.  Purified ER was incubated with recombinant
E1, E2, ATP, ubiquitin, and immobilized SCFb-TRCP isolated from animal cells by virtue of
Flag tags on co-transfected Cul1 and b-TRCP.  Reactions were supplemented with the
indicated concentration of Protac-2, incubated for 60 minutes at 30°C, and monitored by
SDS-PAGE followed by immunoblotting with an anti-ER antibody. (B): Protac-2 induces
assembly of high molecular weight multiubiquitin chains on ER.  Same as (A), except that
methyl ubiquitin was added in the place of ubiquitin (lane 4).  (C): Estradiol and IkBa
phosphopeptide must be covalently linked to promote ER ubiquitination.  The reaction was
as described in (A), except that IkBa phosphopeptide and estradiol (5mM) were separately
added to the ubiquitination reaction instead of Protac-2.  (D and E): Free
IkBa phosphopeptide (D) and estradiol (E) compete out Protac activity.  Same as (A),
except that Protac-2 was used at 1 mM.  Increasing amounts of IkBa phosphopeptide (lanes
2-5) or 10 mM of IkBa peptide that is unphosphorylated (lane 6, arrow) was added to
ubiquitination reaction.  (F): Protacs are target-specific.  Same as (A), except that zap70-
ovalicin and IkBa phosphopeptide-DHT Protacs were used in place of Protac-2, as
indicated.
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Figure IV-3.  Ubiquitinated ER is degraded by the 26S proteasome.  (A):
Ubiquitination reactions performed as described in the legend to Fig. 2A were
supplemented with purified yeast 26S proteasomes.  Within 10 minutes, complete
degradation of ER was observed.  (B): Purified 26S proteasome preparations were
preincubated in 1,10 phenanthroline (1 mM) or 1,7 phenanthroline (1 mM) prior to
addition. The metal chelator 1,10 phenanthroline inhibits the Rpn11-associated
deubiquitinating activity that is required for substrate degradation by the proteasome.
Degradation of ER was inhibited by addition of 1,10 phenanthroline, but not the inactive
derivative 1,7 phenanthroline.
86
 
87
88
Figure IV- 4.  Microinjection of Protac leads to GFP-AR degradation in cells.  Protac-
3 (10mM in the microinjection needle) was introduced using a Picospritzer II pressurized
microinjector into 293AR-GFP cells in a solution containing KCl (200 mM) and rhodamine
dextran (50 mg/ml).  Approximately 10% of total cell volume was injected.    (A): Protac-3
induces GFP-AR disappearance within 60 minutes.  The top panels show cell morphology
under light microscopy overlaid with images of cells injected with Protac as indicated by
rhodamine fluorescence (pink color).  The bottom panels show images of GFP
fluorescence.  By one hour, GFP signal disappeared in almost all microinjected cells.  To
quantitate these results, we injected over 200 cells and classified the degree of GFP
disappearance as being either none (1), minimal (2), partial (3), or complete (4).  Examples
from each category and the tabulated results are shown in (B).  These results were
reproducible in three independent experiments performed on separate days with 30 to 50
cells injected per day.  (C): Same as (A), except that 293 cells expressing GFP-AR were
microinjected with free IkBa phosphopeptide (IkBapp) plus testosterone (test) (D-F):
Same as (A) except that 293AR-GFP cells were microinjected with Protac (10 mM) plus 10-
fold molar excess (100 mM) of IkBa phosphopeptide (IkBapp) (D), testosterone (test) (E),
or proteasome inhibitor epoxomicin (10 mM) (F).  (G): Same as (A) except that 293AR-GFP
cells were microinjected with Protac-2.  The controls shown in (C)-(G) confirm that Protac-
dependent turnover of AR-GFP depended on intact Protac, and was both saturable and
specific.
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CHAPTER V
Targeting the Androgen Receptor for Degradation with a Cell-Permeable Protac
The data presented in this chapter were generated in collaboration with John S.
Schneekloth, Jr., Fabiana Fonseca, Michael Koldobskiy, Amit Mandal, and Craig M.
Crews.  This work was submitted (Schneekloth, et al.; Appendix).
Introduction
Due to the success of the microinjection experiments with the
IkBa phosphopeptide-DHT Protac, we chose to develop a Protac that was capable of
entering cells.  To this end, our collaborator Craig Crews synthesized a Protac containing
the HIF-1 binding peptide ALAPYIP that associates with the ubiquitin ligase, VHL (Von-
Hippel-Lindau tumor suppressor (1).  This sequence has been shown to be the minimum
recognition domain for VHL (2), which serves as the substrate receptor for the ubiquitin
ligase complex.  Under normoxic conditions, a proline hydroxylase catalyzes the
hydroxylation of hypoxia inducible factor 1a (HIF1a), resulting in recognition and
polyubiquitination by VHL.  HIF1a is thus constitutively ubiquitinated and degraded under
normoxic condition.  In addition to the HIF1a peptide, an HIV tat poly-D-arginine tag was
added on the carboxy terminus to facilitate cell entry and resist nonspecific proteolysis (3,
4, 5).  Because a molecule fused to the polyarginine sequence should in principle be cell
permeable, the Protac would not need to be microinjected.  This HIF-polyarginine-DHT
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Protac was tested to potentially develop a novel strategy to inhibit the progression of
prostate cancer.
Results
The androgen receptor (AR) has been shown to promote  the growth of hormone
sensitive prostate tumors.  In fact, patients diagnosed with androgen-responsive prostate
tumors receive hormonal therapy to control tumor growth, however, these approaches
produce significant side effects.  There is recent evidence that in androgen-independent
prostate tumors, AR can still promote tumor growth.  To test the hypothesis that a cell
permeable Protac could lead to the degradation of a tumor-promoting protein such as AR, a
Protac was synthesized consisting of the HIF-D-Arg peptide linked to the ligand for the
androgen receptor, dihydroxytestosterone (DHT).
To determine whether a cell-permeable HIF-DHT Protac could promote
degradation of AR, we treated 293 cells stably expressing GFP-AR (293AR-GFP) with
increasing concentrations of Protac (Fig. 1A and B).  Within one hour, we observed
significant decrease in GFP-AR signal in cells treated with 100, 50, and 25 mM Protac, but
not DMSO control.  Western blot analysis with anti-AR antisera (UBI) verified the
downregulation of AR in cells treated with 25mM Protac compared to DMSO control or
untreated cells (Fig. 1B, bottom panel).  Parental 293 cells do not express GFP-AR and
therefore was a negative control.  Concentrations lower than 25 mM did not result in GFP-
AR degradation (data not shown).
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To assess whether Protac-induced degradation was proteasome-dependent, we
treated cells with the irreversible proteasome inhibitor, epoxomicin (Fig. 1C, top left
panel).  Cells were pretreated with 10 mM epoxomicin for 4 hours prior to treatment with
25 mM Protac.  Protac-dependent loss of GFP fluorescence was inhibited in cells treated
with epoxomicin (Fig. 1C, middle panel) in comparison to cells pretreated with DMSO
control followed by Protac (Fig. 1C, right panel).  These results demonstrate that the cell
permeable HIF-DHT Protac increases the turnover of GFP-AR in cells.  Western blot
analysis confirmed that decreased GFP-AR fluorescence was due to a decrease in GFP-AR
protein (Fig. 1C, bottom panel), which was inhibited when cells were treated with
epoxomicin (10 mM).
We next performed experiments to characterize the dependence of GFP-AR
degradation on the HIF-D-arg peptide and DHT moieties of Protac.  293 AR-GFP cells were
treated for one hour with Protac in addition to 10-fold molar excess of testosterone or HIF-
D-Arg peptide (Fig. 2d and e).  Both testosterone and HIF-D-Arg peptide completely
inhibited degradation of GFP-AR by competing with the Protac.  Moreover, when added
together as separate compounds, HIF-D-Arg and testosterone (25 mM) failed to reproduce
the effect of intact HIF-DHT Protac (Fig. 2f).  Neither testosterone nor HIF-D-Arg peptide
alone had any effect on GFP-AR degradation (Fig. 2g and h).  Therefore, these results are
consistent with our hypothesis that HIF-DHT Protac acts as a bridging molecule in that one
moiety of the Protac, consisting of DHT, associates with the AR, while the other moiety,
HIF-D-Arg recruits the AR to the VHL ubiquitin ligase.
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To determine whether the HIF-DHT Protac could affect the function of AR, we
transiently transfected a plasmid containing two copies of the androgen receptor response
region in the rat probasin promoter (ARRE2BP) fused to a luciferase reporter gene (6)
(kindly provided by Charles Sawyers) into 293AR-GFP cells.  Our results demonstrated that at
4 and 24 hours, there was a 50% decrease in relative luciferase activity in cells treated with
Protac (Fig. 3).  The difference in activity between Protac treated and DMSO (control)
treated cells was statistically significant (p<0.05).  These experiments were performed in
triplicate and on at least two different days. The luciferase activity was normalized using
CMVb-galactosidase as the internal control.  Our preliminary results suggest that not only
does cell permeable HIF-DHT Protac lead to degradation of AR in cells, but it also inhibits
AR function.
Discussion
These experiments demonstrate that similar to Protac microinjections, a cell
permeable Protac can target the AR for degradation in cells.  In one sense, Protacs could be
used to target any protein within a cell and selectively initiate its degradation, resulting in
inhibition of protein function. The advantage of Protacs is that proteolysis is not dependent
on the active site inhibition of the target since any unique site of a protein may be targeted,
provided there are exposed lysines within proximity for the attachment of ubiquitin.
Furthermore, because some E3 ligases are expressed in a tissue specific manner, this also
raises the possibility that Protacs could be used as tissue specific drugs.  
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Future work will focus on the treatment of prostate cancer cells to examine the
effects of Protacs on the regulation of endogenous AR, AR function, and cell proliferation.
Furthermore, obtaining an efficient drug may depend on a small molecule identified from a
chemical library screen that will replace the peptide moiety of Protacs.  The goals of future
experiments will be to test other Protacs in the context of tumor cells, e.g., breast cancer,
followed by preclinical studies in animal models.
In theory, with cell permeable Protacs, one could control a desired cellular
phenotype, such as inhibition of a critical transcription factor that is challenging to target
pharmaceutically.  “Chemical knockout” of a protein could provide an alternative for a
genetic knockout, which would be invaluable in the study of protein function.  Another
potential use of Protacs would be to use diversified libraries to screen for phenotypic
effects in a chemical genetic manner.  This strategy could be used to identify novel ligands
for a target or potentially new protein targets by studying phenotypic changes that result
from selective protein degradation.  Finally, Protacs could act as drugs to remove toxic or
disease-promoting proteins.  This strategy may be particularly useful since many diseases,
including cancers, are dependent on overexpression of a small number of proteins,
including oncogenes.  In summary, the expanding potential applications for this technology
suggest that Protacs may be widely used in the areas of cell biology, biochemistry, and
medicine.
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Experimental Procedures
Tissue culture and transfections
293 cells were cultured in DMEM with 10% (vol/vol) FBS (GIBCO), penicillin
(100 units/ml), streptomycin (100 mg/ml), and L-glutamine (2 mM).  Cells were split 1:5
the day prior to transfection and were 70% confluent in 100-mm dishes on the day of
transfection.  293 cells were transfected with 20 mg of GFP-flag-AR expression plasmid
(kindly provided by Charles Sawyers, Howard Hughes Medical Institute, UCLA) using
calcium phosphate precipitation method.  Cells were selected with G418 (600 mg/ml) to
establish stable lines.  Western blot analysis was performed to document expression of AR
(data not shown).
         To assess the effects of Protac on AR function, we transiently transfected a plasmid,
ARRE2PBLuc, which contains two androgen response regions in the rat probasin promoter
from nucleotides –244 to –96 fused to luciferase (6).  Twenty micrograms of ARRE2Luc
and 1 mg of CMVb-galactosidase plasmid were added to 0.3 ml of 293 cells stably
expressing GFP-AR (resuspended in RPMI and 20% FBS), placed on ice for 5 minutes,
and electroporated  (200 Volts, 960 capacitance; BioRad Inc.).  Cells were resuspended in
MEM and plated into 6-well plates with Protac (30 mM) or DMSO control. Cells were
harvested at the indicated timepoints and lysed using the Lysis Reporter Buffer (Promega,
Inc.).  Luciferase and b-galactosidase activity were determined according to standardized
methods (Promega, Inc.).  Statistical analysis was performed using the JmpIn program.
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For GFP-AR degradation experiments, we plated 200 ml of cells at a density of 0.3 or
0.5 X 106 cells/ml in 96-well dishes.  Protac was reconstituted in DMSO (20 or 10mM
stock) to minimize the volume added to cells to 0.5 ml per well for a final concentration  of
50 mM.  We treated cells with Protac or appropriate controls for one hour.  For proteasome
inhibition experiments, epoxomicin (10mM final concentration) was added to cells for 4
hours prior to adding Protac.
Western blot analysis-Cells were lysed with boiling SDS-laemmli buffer and boiled for 5
minutes.  Equal volume of lysate was loaded onto an 8% SDS-polyacrylamide gel and
transferred onto a nitrocellulose membrane.  Immunoblotting was performed with blocking
buffer (3% milk, 0.1% Triton-X) and rabbit polyclonal anti-AR antisera (1:1000, UBI) or
anti-b-tubulin antisera (1:200, Santa Cruz).  ECL chemiluminescence was used as the
detection method.
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Figure V-1.  HIF-DHT Protac mediates GFP-AR degradation in a proteasome-
dependent manner.
293AR-GFP cells (0.5 X 106 cells/ml) were plated at 50% confluence in a volume of 200 ml of
media in a 96-well dish.  (A and B):  Protac induces GFP-AR disappearance within 60
minutes.  Either 100, 50, or 25 mM concentration of Protac or DMSO control in a volume
of 0.6 ml was added.  Cells were visualized under light (top) or fluorescent (bottom)
microscopy one hour after treatment.  Photographs were taken with a SC35 type 12, 35 mm
camera attached to an Olympus fluorescent inverted microscope.  (B): GFP-AR protein is
decreased in cells treated with Protac.  Lysates were prepared from parental cells (293 par)
or GFP-AR expressing cells treated with Protac (+PT), DMSO, or no treatment (None) for
60 minutes. Western blot analysis was performed with rabbit polyclonal anti-AR antisera
(1:1000; UBI) or b-tubulin (1:200; Santa Cruz).  (C):  Epoxomicin inhibits Protac-induced
degradation of GFP-AR.  Cells were plated at a density of 0.3 X 106 cells/ml and treated
with 10 mM epoxomicin (Calbiochem) or DMSO for 4 hours prior to adding Protac (25
mM) for 60 min.  (D): Western blot analysis was performed with cells in 96-well dishes
treated with Protac (25 mM), DMSO (left); epoxomicin (10 mM), epoxomicin (10 mM) +
Protac (50 or 25 mM), or Protac alone (50 or 25 mM).  These results were reproducible in at
least two separate experiments performed in duplicate on different days.
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Figure V-2.  The linkage of HIF-D-arg peptide and testosterone is required for HIF-
DHT-induced degradation of GFP-AR.
293AR-GFP cells were plated at a density of 0.3 X 106 cells/ml in 96-well dishes containing
200 ml cells/well.  Cells were treated with either (a) no treatment, (b) DMSO (equal
volume), (c) HIF-DHT Protac (25 mM) alone, (d) Protac + 10-fold molar excess (250 mM)
testosterone or (e) Protac + 10-fold molar excess (250 mM) HIF-D-Arg peptide (HIF-D-
Arg), (f) HIF-D-Arg peptide (25 mM) + testosterone 25mM together added separately, (g)
testosterone (25 mM) alone, or HIF-D-Arg peptide (25 mM) alone.  These data are
representative of two independent experiments performed on different days.
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Figure V-3.  Protac inhibits ARRE2PBLuciferase activity.  293 cells stably expressing
GFP-AR were transiently transfected with a plasmid containing two copies of the AR
response region in the rat probasin promoter fused to a luciferase reporter gene.  Cells were
treated with HIF-DHT Protac (30 mM) or DMSO control at the indicated timepoints.
Protac significantly inhibits AR transcriptional activation of ARRE2PBLuc (p<0.05).
These experiments were performed in triplicate and on at least two different days.
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CHAPTER VI
Future Questions
There are still several questions that will need to be answered before this technology can be
considered for therapeutic applications:
1.  How can we facilitate entry of Protacs more readily into cancer cells?
2.  Does Protac degrade endogenous AR or ER in prostate or breast cancer cells,
respectively?
3.  Which ubiquitin ligases are optimal to target proteins for  ubiquitination and
degradation?
4. Which targets would be most amenable to targeted ubiquitination and degradation by
Protacs in cancer therapy?
5.  What will be the effect on  the efficiency of Protacs by replacing the peptide moiety
with a small molecule?
6.  What are the effects of Protacs on cell proliferation, cell cycle progression, and
survival?
7.  Are Protacs effective in vivo, i.e., mouse models of cancer?
8.  Will Protacs be a viable molecular therapeutic approach for the treatment of human
disease?
